Document:

License Agreement, dated March 15, 2005

 Exhibit 10.3 
 License Agreement 
 This Agreement is entered into on the Effective Date (as defined below) by and 
 between 
 F. Hoffmann-La Roche Ltd 
 with an office and place of business at Grenzacherstr, 124, CH-4070 Basel. Switzerland (“ROCHE Basel”) 
 and 
 Hoffmann-La Roche Inc. 
 with an office and place of business at 340 Kingsland Street, Nutley, NJ 07110, USA (“ROCHE Nutley”; ROCHE Basel and ROCHE Nutley together referred to as
“ROCHE”) on the one hand 
 and 
 Evotec Neurosciences
GmbH, Schnackenburgallee 114, 22525 Hamburg, Germany (“ENS”) 
 WHEREAS, ROCHE is the owner of certain patent rights and know-how
relating to the Compound (as defined below); and 
 WHEREAS, ENS wishes to perform certain development work with respect to the Compound with
the purpose of filing an NDA or equivalent in other countries in order to obtain marketing approval in the Territory and to subsequently market the Product; and 
 WHEREAS, ENS wishes to obtain, and ROCHE wishes to grant rights and licenses under the ROCHE Patent Rights and ROCHE Know-How (as defined below); and 
 NOW, THEREFORE, in consideration of the mutual promises and covenants contained in this Agreement, the parties agree as follows: 
  
  
 * Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 

	1.	Definitions 

  

	 	1.1	“Affiliate” shall mean with respect to either party (i) an entity which owns, directly or indirectly, a controlling interest in such party, by stock ownership
or otherwise; or (ii) an entity which is owned by such party, either directly or indirectly, by stock ownership or otherwise; or (iii) an entity, the majority ownership of which is directly or indirectly common to the majority ownership of
such party. Anything to the contrary in this paragraph notwithstanding, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080-4990, U.S.A. (“Genentech”) and Chugai Pharmaceutical Co., Ltd, 1-9, Kyobashi 2-chome, Chuo-ku, Tokyo,
104-8301, Japan (“Chugai”) shall not be deemed an Affiliate of ROCHE unless ROCHE notifies ENS that ROCHE wishes for Genentech, Inc. and/or Chugai Pharmaceutical Co., Ltd, to be deemed an Affiliate of ROCHE. 

  

	 	1.2	“Commercially Reasonable Efforts” shall mean those efforts, activities and measures, which a diligent Third Party company active in a similar field as the
respective party, would consider to be commercially reasonable, feasible and viable to be performed, undertaken or made in or under the specific circumstances. 

  

	 	1.3	“Compound” shall mean the GABA-A receptor modulator **** 

  

	 	1.4	“Confidential Information” shall mean any and all information, data or know-how, whether technical or non-technical, oral or written, related to the Compound and
the Product that is disclosed by one party or its Affiliates (“Disclosing Party”) to the other party or its Affiliates (“Receiving Party”). Confidential Information shall not include any information, data or know-how which:

 1.4.1 either before or after disclosure to the Receiving Party, was or becomes published or generally known to the public
through no fault or omission on the part of the Receiving Party; or 
 1.4.2 was known or used by the Receiving Party prior to its disclosure
by the Disclosing Party to the Receiving Party; or 
  
  
 * Portions of this document marked with **** have been
omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 2 

 1.4.3 either before or after disclosure to the Receiving Party, is provided to the Receiving Party by a
Third Party having the right to do so; 
 1.4.4 is independently developed by the Receiving Party without reference to any Confidential
Information previously disclosed by the Disclosing Party; or 
 1.4.5 is required to be disclosed by the Receiving Party to comply with
applicable laws, to defend or prosecute litigation or to comply with governmental regulations, provided that, the Receiving Party provides prior written notice of such disclosure to the Disclosing Party and, to the extent practicable, requests
confidential treatment (where available) or takes reasonable and lawful actions to minimize the degree of such disclosure. 
  

	 	1.5	“Development Plan” shall mean the ENS Development Plan for the development of the Compound, attached to this Agreement as Appendix 3. 

  

	 	1.6	“Effective Date” shall mean March 15, 2005. 

  

	 	1.7	“EMEA” shall mean the European Medicines Agency and any successor agency thereof. 

  

	 	1.8	“ENS Patent Rights and Know-How” shall mean all information, data and know-how, improvements, inventions, discoveries and other technology, whether or not
patentable, made or developed by or on behalf of ENS in the course of its activities pursuant to this Agreement, which relate to a Compound or Product, and any patents, patent applications, or other intellectual property rights based on the
foregoing (“ENS Patent Rights”), including, by way of example only, all divisionals, continuations, continuations-in-part, re-examinations, reissues, extensions, registrations, confirmations and supplementary or complementary certificates
and the like with respect to any of the foregoing. 

  

	 	1.9	“FDA” shall mean the U.S. Federal Food and Drug Administration and any successor agency thereof. 

  
  
 * Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 3 

	 	1.10	“Field” shall mean CNS indications where the compound shows potential therapeutic benefit, for example such as treatment and prevention of insomnia, anxiety and
Generalized Anxiety Disorder (GAD). 

  

	 	1.11	“First Commercial Sale” shall mean the first invoiced sale of a Product by ENS or its respective Affiliates,
sub-licensees, distributors or marketing partners. 

  

	 	1.12	“Marketing Authorization” shall mean such governmental approval (including pricing approval, where required) for the marketing of a Product in a country of the
Territory as is necessary to enable sale and distribution of the Product in such country, which approval results from an NDA Filing, European equivalent, or an equivalent filing elsewhere. 

  

	 	1.13	“NDA Filing” shall mean a New Drug Application filed as a result of activities under this Agreement with the FDA, or the equivalent application to the equivalent
agency in any other country of the Territory, the filing of which is necessary to market and sell a Licensed Product, including all amendments and supplements to any of the foregoing. 

  

	 	1.14	“Net Sales” and the related term “Adjusted Gross Sales” shall mean for either party distributing and selling Product (in this Section the
“Selling Party”): 

 1.14.1 Adjusted Gross Sales shall mean the gross sales of Products as invoiced by the
Selling Party or its Affiliates, sub-licensees or its marketing partners to Third Parties, less deductions for returns (including withdrawals and recalls), rebates (price reductions including Medicaid and similar types of rebates, e.g. chargebacks),
volume (quantity) discounts granted at the time of invoicing, sales taxes and other taxes directly linked and included in the gross sales amount for the countries concerned in accordance with the Selling Party’s then current standard practices,
whereby the amount of such sales in foreign currencies is converted into US Dollars or Euros, as applicable. 
 1.14.2 Net Sales shall
mean the amount calculated by subtracting from Adjusted Gross Sales a lump sum deduction of **** of Adjusted Gross Sales for those sales-related deductions that are not accounted for on a product-by-product 
  
  
 * Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 4 

 
basis (e.g. outward freights, postage, transportation insurance, packing materials for dispatch of goods, custom duties, discounts granted later than at the
time of invoicing, cash discounts and other direct expenses). 
  

	 	1.15	“Phase III Initiation” shall mean the date of first administration of Product to a patient in a third phase of human clinical trials required by the FDA or European
equivalent to gain evidence of efficacy of Product in a target population, and to obtain expanded evidence of safety for Product that is needed to evaluate the overall benefit-risk relationship of Product and provide an adequate basis for physician
labeling, as described in 21 CFR Part 312(c), as it may be amended (or its successor regulation). 

  

	 	1.16	“Product” shall mean any pharmaceutical dosage form that includes Compound as active pharmaceutical ingredient. 

  

	 	1.17	“ROCHE Know-How” shall mean ROCHE information and data including but not limited to notes, correspondence, certificates, results and official correspondence as
specified in Appendix 2. 

  

	 	1.18	“ROCHE Patent Rights” shall mean the patent applications and patents listed in Appendix 1. 

  

	 	1.19	“Royalty Term” shall mean, with respect to each Product in each country, the period of time commencing on the First Commercial Sale of such Product in such country
and ending on the later of the date that is (a) 10(ten) years after the date of the First Commercial Sale of such Product in such country, and (b) the expiration of the last to expire Valid Patent Claim in such country claiming the
manufacture, use, import, offering for sale, or sale of such Product. With regard to the calculation of the 10(ten) year period, the EU shall be considered as one country. 

  

	 	 1.20
	 “Second Payment” shall mean the payment due on or before October 17th, 2005 as described in Section 5 below. 

  

	 	1.21	“Territory” shall mean all countries and territories of the world. 

  
  
 * Portions of this
document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 5 

	 	1.22	“Third Party” shall mean an entity other than a party to this Agreement and its respective Affiliates, if any. 

  

	 	1.23	“Valid Patent Claim” shall mean either (a) a claim of an issued and unexpired Roche Patent Right which has not been revoked or held unenforceable or invalid by
a decision of a court or other governmental agency of competent jurisdiction, unappealable or unappealed within the time allowed for appeal, and which has not been admitted to be invalid or unenforceable through reissue, disclaimer or otherwise, or
(b) a claim of a pending patent application that is a ROCHE Patent Right. 

  

	 	1.24	In the definitions, the singular shall include the plural and vice versa. 

  

	2.	Grant of Rights 

  

	 	2.1	License Grant. ROCHE Nutley for the US territory and ROCHE Basel for the rest of the Territory (other than the US territory) hereby grant to ENS a worldwide, exclusive
(even as to Roche) right and license to develop, to make, have made, use, offer for sale, sell and import Compound and Products in the Territory in the Field, under the ROCHE Patent Rights and the ROCHE Know-How. 

  

	 	2.2	Right to Sublicense. ENS shall have the right to sublicense its rights under Section 2.1. 

  

	3.	Transfer of ROCHE Know-How and Compound 

  

	 	3.1	Access to ROCHE Know-How. Within forty five (45) days after the Effective Date, ROCHE shall provide to ENS the ROCHE Know-How, which is listed in Appendix 2.

  

	 	3.2	During the Term of this Agreement, ROCHE shall at all times have full access to the ROCHE Know-How. 

  
  
 * Portions of this
document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 6 

	 	3.3	Supply of Compound. 

 3.3.1 Upon request of
ENS, ROCHE shall supply to ENS at cost 2 g of reference samples of Compound for research purposes only. 
 3.3.2 Upon request of ENS, ROCHE
shall supply to ENS samples for clinical trials at a cost of CHF 60,000 per kg. However, the supply of Compound under this Section 3.3. shall be limited to the following Compound existing and available at ROCHE: 
 lot # 8 11 02B 2203 01 - 13. Nov. 1998 - **** approx. 35g on stock, milled 
 lot# 9 07 038 2203 01 - 29. Jul. 1999 - **** approx. 3.447kg on stock, milled 
 lot # 9 07 04B 2203 01 -
Aug. 1999 - **** ca. approx. 0.859kg on stock (Non-GMP), milled 
 ROCHE gives no warranty as to purity or quality of the Compound, which is
transferred in current state only. ROCHE shall have no obligation to perform any work related to the Compound (e.g. research, development, manufacturing work) for ENS. However, Roche will provide last existing measures of the purity of the Compound
to ENS. 
  

	4.	Diligence 

  

	 	4.1	ENS Diligence and Reporting. 

 4.1.1 At all
times during the term of this Agreement, ENS will use and will cause its Affiliates, sub-licensees and marketing partners (if any) to use Commercially Reasonable Efforts to proceed with the development, manufacture, marketing, distribution and sale
of the Compound and/or Product. 
  
  
 * Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 7 

 4.1.2 During the term of this Agreement, at each anniversary of the Effective Date, ENS shall provide
ROCHE with 
 a) a written summary report on the status of development of the Compound; 
 b) all approvals received by ENS, its Affiliates and sub-licensees (if any). 
 ENS shall supplement such written documents as reasonably requested by ROCHE, but shall have no obligation to make such supplements more than twice in any calendar year. 
 4.1.3 If ROCHE reasonably believes that ENS is not using Commercially Reasonable Efforts with respect to the development or commercialization of the
Compound, then ROCHE may provide ENS written notice specifying in reasonable detail the reasons why ROCHE believes that ENS is not using Commercially Reasonable Efforts with respect to the Compound. Upon receipt of such notice, ENS shall have a
period of ninety (90) days to present evidence to ROCHE that ENS is using Commercially Reasonable Efforts with respect to the Compound or to cure the lack of diligence based on the reasons submitted by ROCHE (“Evidence and Cure
Period”). If ENS presents evidence reasonably acceptable to ROCHE, then ROCHE’s notice shall be deemed withdrawn and of no effect. If, within such period, ENS has not presented evidence reasonably acceptable to demonstrate that ENS has
used Commercially Reasonable Efforts to develop the Compound and has not cured such lack of diligence within such period, then ROCHE shall have the right to terminate this Agreement for the Compound in question with immediate effect and
Section 13, shall apply. 
  

	5.	Down Payment. 

 As consideration for the grant of the rights and licenses hereunder, ENS shall pay to ROCHE a down payment in the amount of Five Hundred Thousand US Dollars (US$500,000) payable within thirty (30) days after the
Effective Date. In addition, ENS shall pay to ROCHE a second down payment in the amount of Five Hundred Thousand US Dollars (US$500,000) payable not later than October 17th, 2005. 
  
  
 * Portions of this document marked with **** have been
omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 8 

	6.	Payments to ROCHE. 

  

	 	6.1	ENS shall pay to ROCHE for a Product, the following amounts in accordance with and at the times set out the following milestones 

  

				
	 Milestones
	  	(US$)
	 Phase III Initiation
	  	US$	 ****
	 NDA Filing of first indication in US
	  	US$	 ****
	 NDA Filing of first indication in EU
	  	US$	 ****
	 First Commercial Sale in US
	  	US$	 ****
	 First Commercial Sale in EU
	  	US$	 ****
	 First time Net Sales exceed US$ ****
	  	US$	 ****
	 First time Net Sales exceed US$ ****
	  	US$	 ****

 All milestone payments under Section 6.1. shall be payable within thirty (30) days as
from achievement of the respective milestone by ENS but only once, irrespective if how many times such milestone is achieved. 
  

	 	6.2	Royalties. 

 6.2.1 During the Royalty Term, ROCHE
shall pay to ENS royalties on Net Sales of Product calculated separately in respect of each band of income in each calendar year at the rate of royalty set out opposite the relevant band in the table below: 
  

			
	 Royalties
	  	(US$)
	 Royalties on Net Sales below ****
	  	****
	 Royalties on Net Safes above ****
	  	****

 6.2.2 Royalties Due Once. The obligation to pay royalties to ROCHE under this Agreement is
imposed only once with respect to the same unit of Product. Sales of Product among ENS, its Affiliates and sub-licensees shall not be subject to a royalty, but shall become subject to a royalty only when sold to a Third Party. 
  
  
 * Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 9 

	 	6.3	The payments to be made under this Section 6 shall not include VAT, if any be due and payable thereon. 

  

	7.	Accounting Period and Royalty Reporting 

  

	 	7.1	Accounting Period and Net Sales Accounting. An Accounting Period commencing semiannually respectively on January 1 and July 1, each being the first day of an
Accounting Period, and finishing respectively on June 30 and December 31, each being the last day of an Accounting Period. Royalties on Net Sales shall be paid in US$. Royalties on Net Sales shall be calculated semiannually as of
June 30 and December 31 and shall be paid within the ninety (90) days after the end of each Accounting Period in which such Net Sales are done. With respect to royalties due on Net Sales in the United States, the parties may elect to
report and have paid such royalties directly from one of its Affiliates in the United States. Whenever for the purpose of calculating royalties conversion from any foreign currency shall be required, such conversion shall be made when calculating
the Adjusted Gross Sales, the amount of such sales in foreign currencies shall at first be converted into EURO in accordance with then current standard practices at ENS or ENS sub-licensee. 

  

	 	7.2	Blocked Countries. If by reason of law a Party (“Paying Party”) is unable to convert to EURO or U.S. Dollars a portion of the amount due by it under this
Agreement, then such Party shall notify the other Party in writing and the other Party shall have the right to receive such portion. Upon written request from the other Party, the Paying Party shall pay to the other Party such portion, in the
currency of any other country designated by the other Party and legally available to the Paying Party. 

  

	 	7.3	Royally Reports. Each royalty payment shall be accompanied by a report summarizing for each Product the total Adjusted Gross Sales and Net Sales achieved during the
relevant six-month period, the currency conversion rates, if applicable, which royalty calculation is being applied, the total royalty payments due and the taxes withheld in accordance with Section 7.4. below, if any. 

 
  
 * Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 10 

	 	7.4	Withholding Taxes. If provision is made in law or regulation of any country for withholding of taxes of any type, levies or other charges with respect to any royalty payable
under this Agreement, the party required to do so shall promptly pay such tax, levy or charge for and on behalf of the other party to the proper governmental authority. The paying party shall be entitled to deduct any such tax, levy or charge
actually paid from royalty due or, if no further payments are due, be promptly reimbursed by the other party, provided however that each party agrees to assist the other party, as may reasonably be necessary, in claiming exemption from such
deductions or withholdings under double taxation or similar agreement or treaty from time to time in force and in minimizing the amount required to be so withheld or deducted, and provided further that the paying party shall provide such additional
documentation from time to time as is needed for the other party to confirm the payment of tax. 

  

	 	7.5	Audit and Inspection. ENS and its Affiliates, sub-licensees and marketing partner, if any, shall keep, full, true and accurate books of account containing all particulars
that may be necessary for the purpose of verifying Net Sales and Adjusted Gross Sales and calculating all royalties payable to ROCHE. Such books of accounts shall be kept at their principal place of business. ROCHE or its authorized independent
public accountant has the right to engage, at its own expense, an independent public accountant of international reputation to perform, on behalf of ROCHE or its independent public accountant, an audit, conducted in accordance with international
accounting and auditing standards (IAAS), of such books and records of ENS and its Affiliates, sub-licensees and marketing partners, if any, that are deemed necessary by ROCHE to report on Net Sales of Product for the period or periods requested by
ROCHE and the correctness of any report or payments made under this Agreement. Upon timely request and at least thirty (30) days’ prior written notice from ROCHE, such audit shall be conducted as an additional audit work during the
ENS’s annual audit of the countries specifically requested by ROCHE, during regular business hours in such a manner as to not unnecessarily interfere with ENS’s normal business activities, and shall be limited to results in the two
(2) full calendar years prior to audit notification. Such audit shall not be performed more frequently than once per calendar year nor more frequently than once with respect to records covering any specific period of time. All information,

  
  
 * Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 11 

	 	 
data, documents and abstracts herein referred to shall be used only for the purpose of verifying royalty statements or compliance with this Agreement, shall
be treated as ENS Confidential Information. Audit results shall be shared by and be binding upon the parties. If the audit reveals an overpayment, ROCHE shall promptly reimburse ENS for the amount of the overpayment. If the audit reveals an
underpayment, ENS shall promptly make up such underpayment. If the audit reveals that the royalties owed by ENS for the countries specifically requested and for any calendar year in total have been understated by more than 10% (ten), ENS shall, in
addition, pay the reasonable costs of such additional audit work. The failure of ROCHE to request verification of any royalty calculation within the period during which corresponding records must be maintained will be deemed to be acceptance of the
royalty reporting. 

  

	8.	Intellectual Property 

  

	 	8.1	Inventions. ROCHE and ENS recognize that during the Term of this Agreement inventions relating to the making, using or selling of Compound and/or Product may be generated and
result in patents. Therefore, the parties agree as follows: 

 8.1.1 As to the inventions made solely by person(s) under the
control of ENS in the Field, ENS shall have all of the rights it is entitled to receive from such employee(s) or person(s) and shall become automatically ENS Patent Rights; 
 8.1.2 As to any inventions made solely by person(s) under control of ROCHE in the Field, ROCHE shall have all of the rights they are entitled to receive
from such person(s) and shall become automatically ROCHE Patent Rights; 
 8.1.3 Any inventions made jointly by persons under the control of
both parties during the term of this Agreement in the Field shall be owned jointly by ROCHE and ENS and shall become automatically joint inventions. 
 Both parties represent that each of its or its Affiliates’ respective employees has entered into a written contract of employment that provides for assignment of all inventions made by said employee during the
course of his/her employment to the respective party. 
  
  
 * Portions of this document marked with **** have been
omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 12 

	 	8.2	Trademarks. ENS shall select, own and maintain the trademark(s) for the marketed Products in the Territory. 

  

	 	8.3	Prosecution of Patent Rights. ROCHE shall have the sole responsibility for the prosecution and maintenance of the ROCHE Patent Rights. ROCHE has no obligation to file
additional patents, unless ENS explicitly requests to file an additional patent within ROCHE Patent Rights and agrees to bear the cost and expenses therefore. Otherwise, the costs for the prosecution and the maintenance of the ROCHE Patent Rights
shall be borne by ROCHE. ROCHE shall have the right, but not the obligation, to defend and enforce the ROCHE Patent Rights and ENS Patent Rights. 

 ENS shall have the sole responsibility for the prosecution and maintenance of the ENS Patent Rights. The costs for the prosecution and the maintenance of the ENS Patent Rights shall be borne by ENS, subject to
Section 8.4, below. 
  

	 	8.4	Assignment. If ROCHE is no longer interested in prosecuting or maintaining any of the ROCHE Patent Rights, then ROCHE shall notify ENS thereof. If ENS asks for an assignment
of any such ROCHE Patent Rights, then ROCHE shall assign such ROCHE Patent Rights to ENS free of any charge, provided that ENS shall bear the costs for such assignments. 

 If ENS is no longer interested in prosecuting or maintaining any of the ENS Patent Rights, then ENS shall notify ROCHE thereof. If ROCHE asks for an
assignment of any such ENS Patent Rights, then ENS shall assign such ENS Patent Rights to ROCHE free of any charge, provided that ROCHE shall bear the costs for such assignments. 
  

	 	8.5	Defense and Enforcement. 

 8.5.1
Infringement. Each party shall promptly provide written notice to the other party during the Term of this Agreement of any known infringement or suspected infringement by a Third Party of any ROCHE Patent Rights or ENS Patent Rights, and
shall provide the other party with all evidence in its possession supporting such infringement or unauthorized use or misappropriation. 
  
  
 * Portions of this document marked with **** have been
omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 13 

 8.5.2 Within a period of ninety (90) days after either party provides or receives such written
notice with respect to its Patent Rights (“Decision Period”), the party which Patent Rights are allegedly infringed, in its sole discretion, shall decide whether or not to initiate a suit or take other appropriate action and shall notify
the other party in writing of its decision in writing (“Suit Notice”). 
 8.5.3 If the party which Patent Rights are allegedly
infringed decides to bring a suit or take action and provides a respective Suit Notice, then such party may immediately commence such suit or take such action. If the party which Patent Rights are allegedly infringed (i) does not in writing
advise the other party within the Decision Period that it will commence suit or take action, or (ii) fails to commence suit or take action within a reasonable time after providing Suit Notice, or (iii) abandons an action, then the other
party shall thereafter have the right to commence suit or take action and shall provide written notice to the party which Patent Rights are allegedly infringed of any such suit commenced or action taken by the other party. 
 8.5.4 Upon written request, the party bringing suit or taking action (“Initiating Party”) shall keep the other party informed of the status of
any such suit or action and shall provide the other party with copies of all substantive documents and communications filed in such suit or action. The Initiating Party shall have the sole and exclusive right to select counsel for any such suit or
action. 
 8.5.5 The Initiating Party shall, except as provided below, pay all expenses of the suit or action, including, without limitation,
the Initiating Party’s attorneys’ fees, damages and court costs. Any damages, settlement fees or other consideration received as a result of such suit or action shall belong to the Initiating Party. 
 8.5.6 If the Initiating Party believes it reasonably necessary, upon written request the other party shall join as a party to the suit or action but
shall be under no obligation to participate except to the extent that such participation is required 
  
  
 * Portions of this document marked with **** have been
omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 14 

 
as the result of its being a named party to the suit or action. At the Initiating Party’s written request, the other party shall offer reasonable
assistance to the Initiating Party in connection therewith at no charge to the Initiating Party except for reimbursement of reasonable out-of-pocket expenses incurred by the other party in rendering such assistance. The other party shall have the
right to participate and be represented in any such suit or action by its own counsel at its own expense. 
 8.5.7 The Initiating Party shall
not settle, agree to a consent judgment or otherwise voluntarily dispose of the suit or action without the written consent of the other party, which consent shall not be unreasonably withheld. 
  

	 	8.6	Patent Status 

 8.6.1 Roche will provide ENS with
an updated patent status covering the Compound on an annual basis. 
 8.6.2 Upon ENS’ request, but limited to once a year, ENS shall
have the possibility to access and view all files concerning the patent status of the Compound at the offices of Roche’s patent department. 
  

	9.	Confidential Information 

  

	 	9.1	Non-Use and Non-Disclosure. During the Term of this Agreement and for five (5) years as from its termination for whatsoever reason, a Receiving Party shall
(i) treat Confidential Information provided by Disclosing Party under this Agreement and all previous agreements as it would treat its own information of a similar nature, (ii) take all reasonable precautions not to disclose such
Confidential Information to Third Parties, without the Disclosing Party’s prior written consent, and (iii) not use such Confidential Information other than for fulfilling its obligations under this Agreement. 

  
  
 * Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 15 

	 	9.2	Authorized Disclosure. Nothing in this Agreement shall prevent the Parties from disclosing Confidential Information to (i) Registration Authorities or other governmental
agencies of any country in the Territory to the extent required or desirable to secure government approval for the development, manufacture or sale of Product in the Territory in the Field, (ii) Third Party’s acting on behalf of one Party,
to the extent reasonably necessary for the development, manufacture or sale of Product in the Territory, or (iii) Third Parties to the extent reasonably necessary to market Product in the Territory, always to the extent necessary for such Party
to enjoy all its right under this Agreement. 

  

	10.	Term and Termination 

  

	 	10.1	Term. This Agreement comes into effect on the Effective Date and will remain in force, unless earlier terminated, on a country-by-country and Product-by-Product basis until
expiry of the Royalty Term, whichever is later. Thereafter, the licenses granted hereunder shall be fully paid up and royalty-free. 

  

	 	10.2	Termination. 

 10.2.1 Termination by ENS during the period before the Second Payment. ENS shall have the right to terminate this Agreement in its entirety with 1 (one) days written notice during the period from the Effective
date to October 17th 2005. 
 10.2.2 Termination by ENS after the Second Payment. ENS shall have the right to terminate this Agreement on a country-by-country or Product-by-Product basis at any time with six (6) months prior written notice. 
 10.2.3 Termination for Breach. A Party (“Non-breaching Party”) shall have the right to terminate this Agreement in its entirety or on a
country-by-country or product-by-product basis in the event the other Party (“Breaching Party”) is in breach of any of its material obligations under this Agreement. The Non-breaching Party shall provide written notice to the Breaching
party, which notice 
  
  
 * Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 16 

 
shall identify the breach and the Products and countries in which the Non-breaching party intends to have this Agreement terminate. The Breaching Party shall
have a period of one hundred and twenty (120) days after such written notice is provided to cure such breach. If such breach is not cured within the one hundred and twenty day (120) period, this Agreement shall effectively terminate in
such countries. The waiver by either Party of any breach of any term or condition of this Agreement shall not be deemed a waiver as to any subsequent or similar breach. The waiver by either Party of any breach of any term or condition of this
Agreement shall not be deemed a waiver as to any subsequent or similar breach. The right to terminate this Agreement under this Section 10.2.3 is in addition to any other right and protection that may otherwise be available as a result of a
breach, including, without limitation, the right to damages. 
 10.2.4 Bankruptcy. Either Party may terminate this Agreement at any
time with immediate effect by written notice to the other Party if the other Party is declared bankrupt or insolvent, or if a receiver is appointed, or any procedures are commenced, voluntarily or involuntarily, by or against a Party under any
bankruptcy or similar law, or in the near future it is reasonably anticipated that the Party is to be dissolved, liquidated or bankrupt. 
  

	11.	Consequences of Termination 

  

	 	11.1	Rights and Licenses. Upon termination of this Agreement 

 11.1.1 ENS shall make its personnel and or other resources reasonably available to ROCHE as necessary to effect an orderly transition of development and commercial responsibilities, with the reasonable cost of such personnel and resources
to be born by ENS for such services. 
 11.1.2 All rights and licenses granted by ROCHE to ENS under this Agreement (or, as applicable, in
the country or with respect to that Product) shall terminate on the effective date of termination. In the event of any such termination, the following shall apply and no compensation nor refund shall be due by either Party to the other Party,
otherwise than damages as determined by a court of competent jurisdiction: 
  
  
 * Portions of this document marked with **** have been
omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 17 

 11.1.3 ENS shall, upon ROCHE’s written request, smoothly and promptly assign and transfer to ROCHE,
at no expense to ROCHE, in connection with the Territory or the terminated countries (as applicable), all of ENS’s right, title and interest in and to (i) all trademarks used for Product, (ii) all regulatory filings (such as INDs and
drug master files), regulatory approvals, clinical trial agreements (to the extent assignable and not cancelled), (iii) all data, results, clinical trials data, support documentation having arisen out of the development, materials and other
information, in ENS’s possession and control related to Product in the Territory, and related to ENS’s Patent Rights and Roche Know-How, (iv) all customer lists, marketing and promotional material, and all other documentation related
to marketing, sale, and promotion of the Products in the Territory or in the terminated country (as applicable), and (iv) during the termination notice period provide a reasonable number of person days of qualified personnel to transfer
ENS’s manufacturing technology to ROCHE. With respect to the trademarks, the responsibility of preparing and filing of the documents for the recordal of the assignments with the competent authorities in each applicable country and any action
required ancillary, shall be born by ROCHE. However, each party shall bear its expenses caused by its activities in connection with the assignments and transfer of the trademarks. 
 11.1.4 ENS shall further make Commercially Reasonable Efforts to continue making the Product provided however that, ENS shall transfer at its own
expenses to ROCHE all technical and industrial know how related to the manufacturing of the Product for use by ROCHE and shall provide reasonable assistance and support (up to a reasonable number of person/days of qualified personnel) as may be
reasonably required by ROCHE to be in a position to make the Product itself. 
 11.1.5 ROCHE shall have the right to disclose such filings,
approvals and data to (i) governmental agencies of the country to the extent required or desirable to secure government approval for the development, manufacturing or sale of Product in the country, (ii) Third Parties acting on behalf of
ROCHE, its Affiliates or sublicensees, to the extent reasonably necessary for the development, manufacture, or sale of Product in the country, and (iii) Third Parties to the extent reasonably necessary to market Product in the country.

  
  
 * Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 18 

 11.1.6 For a given Product and country so terminated, or for the Territory in the case of termination of
this Agreement in its entirety, ENS shall grant to ROCHE an exclusive, sub-licensable, royalty-free license under all elements of ENS Patents and Know-how that are not severable from the Product, and a non exclusive, sub-licensable, royalty-free
license under all other ENS Patents and Know-how to make, have made, use, offer for sale, sell and import such Product in such country or the Territory, as applicable. 
 11.1.7 ENS shall agree to take such actions and execute such instruments, agreements and documents as are necessary to affect the foregoing. 
  

	 	11.2	Royalty and Payment Obligations. Expiration of this Agreement pursuant to Section 10.1 above, and termination of this Agreement will release both parties from any
obligation to pay royalties or make any payments to the other party which would otherwise become due or payable on or after the effective date of termination. 

  

	12.	Indemnification 

  

	 	12.1	Indemnification by ROCHE. ROCHE shall indemnify, hold harmless and defend ENS and its directors, officers, employees and agents from and against any and all losses, expenses,
cost of defense (including without limitation attorneys’ fees, witness fees, damages, judgments, fines and amounts paid in settlement) and any amounts ENS becomes legally obligated to pay because of any claim or claims against it to the extent
that such claim or claims arise out of activities related to Product in the Field (e.g. product liability claims) conducted by or on behalf of ROCHE, except to the extent such losses, expenses, costs and amounts are due to the negligence or
misconduct or failure to act of ENS. 

  

	 	12.2	Indemnification by ENS. ENS shall indemnify, hold harmless and defend ROCHE and its directors, officers, employees and agents from and against any and all losses, expenses,
cost of defense (including without limitation attorneys’ fees, 

  
  
 * Portions of this document marked with **** have been
omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 19 

	 	 
witness fees, damages, judgments, fines and amounts paid in settlement) and any amounts ROCHE becomes legally obligated to pay because of any claim or claims
against it to the extent that such claim or claims arise out of activities related to Product in the Field (e.g. product liability claims) conducted by or on behalf of ENS, except to the extent such losses, expenses, costs and amounts are due to the
negligence or misconduct or failure to act of ROCHE. 

  

	 	12.3	Procedure. In the event of a claim by a third party against a party entitled to indemnification under this Agreement (“Indemnified Party”), the Indemnified Party
shall promptly notify the other party (“Indemnifying Party”) in writing of the claim and the Indemnifying Party shall undertake and solely manage and control, at its sole expense, the defense of the claim and its settlement. The
Indemnified Party shall cooperate with the Indemnifying Party and may, at its option and expense, be represented in any such action or proceeding by counsel of its choice. The indemnifying Party shall not be liable for any litigation costs or
expenses incurred by the Indemnified Party without the Indemnifying Party’s written consent. The Indemnifying Party shall not settle any such claim unless such settlement fully and unconditionally releases the Indemnified Party from all
liability relating thereto, unless the Indemnified Party otherwise agrees in writing. 

  

	13.	Representations and Warranties 

  

	 	13.1	Mutual Representations and Warranties. Each party hereby represents and warrants: 

 13.1.1 Authority. Such party has the full right and authority to enter into this Agreement, and that it is not aware of any impediment that would inhibit its ability to perform its obligations under this
Agreement. 
 13.1.2 Material Facts. Such party has disclosed all information in its possession or control which is material to the
other party entering into this Agreement, and such information does not contain any untrue statement of material fact or omit to state a material fact. 
  
  
 * Portions of this document marked with **** have been
omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 20 

	 	13.2	Grants. ROCHE has the right to grant ENS the rights and licenses described in this Agreement. 

  

	 	13.3	Roche Representations and Warranties. ROCHE represents and warrants that, as of the Effective Date, 

 (i) it has no knowledge of any claims by any Third Party that the use of the Compound licensed under the terms and conditions of this Agreement infringes
any proprietary rights of any Third Party, 
 (ii) to the best of its knowledge, the use of the Compound licensed under the terms and
conditions of this Agreement does not infringe any proprietary right of any Third Party, 
 (iii) there are no legal actions, suits or other
proceedings relating to the Compound licensed under the terms and conditions of this Agreement. 
  

	14.	Governing Law and Dispute Resolutions 

  

	 	14.1	Governing Law. This Agreement shall be governed by and construed in accordance with the laws of Switzerland, without reference to its conflict of laws principles, and shall
not be governed by the United Nations Convention of International Contracts on the Sale of Goods (the Vienna Convention). 

  

	 	14.2	Disputes. Unless otherwise set forth in this Agreement, in the event of a dispute arising out of or under this Agreement between the parties, such dispute shall be referred
to the respective executive officers of the parties designated below or their designees, for good faith negotiations attempting to resolve the dispute. The designated executive officers are as follows: 

  

			
	 For ENS:
	 	CEO
		
	 For ROCHE:
	 	Head of Pharma Partnering

  
  
 * Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 21 

	 	14.3	Arbitration. In the event of any controversy or claim arising out of or relating to any provision of this Agreement or the breach thereof, the parties shall try to settle
those conflicts amicably between themselves as set forth in Section 16.2. Should they fail to agree within two (2) months after such dispute has first arisen, any controversy, dispute or claim which may arise out of or in connection with
this Agreement, or the breach, termination or validity thereof, shall be finally settled by arbitration in accordance with the Rules of Conciliation and Arbitration of the International Chamber of Commerce, under preclusion of the otherwise ordinary
recourse to the courts, The arbitral tribunal can also decide about the effectiveness of this arbitration clause. The arbitral tribunal shall consist of three arbitrators. The place of arbitration shall be Zürich, Switzerland. The language to
be used shall be English. 

  

	15.	Publicity 

  

	 	15.1	Press Release. Neither party shall release any information (e.g. press release) related to this Agreement, including its terms, without the prior written consent of the other
party, unless release of such information is required by law. If a party (“Releasing Party”) determines that it is required by law to release information relating to this Agreement to a Third Party, it shall so notify the other party prior
to the release of such information, including the text of the information proposed for release, in sufficient time for the other party to comment. The other party shall have the right to comment regarding the necessity of such disclosure and the
text proposed for disclosure, which comment the Releasing Party must consider and include unless prohibited by law. Not withstanding the above, no press release shall be made prior to payment of the Second Payment unless otherwise decided by ENS.

  

	 	15.2	Disclosure of Information to ENS investors. ENS shall have the right to release any information related to this Agreement, including its terms, to potential investors,
provided that each such investor has previously entered into a written confidentiality agreement at least substantially similar to the confidentiality obligations under Section 9.1. hereof. 

  
  
 * Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 22 

	 	15.3	Publications. ENS shall have the right to publish at any time any results relating to the research and development activities hereunder with respect to Compound or Products
in the Field, provided however that ROCHE receives a copy thereof. 

  

	16.	Miscellaneous 

  

	 	16.1	Survival. Sections 9, 12, 14 shall survive the expiration or termination of this Agreement for any reason. 

  

	 	16.2	Agency. Neither party is, nor will be deemed to be, an employee, agent or representative of the other party for any purpose. Each party is an independent contractor, not an
employee or partner of the other party. Neither party shall have the authority to speak for, represent or obligate the other party in any way without prior written authority from the other party. 

  

	 	16.3	Amendment. No amendment or modification hereof shall be valid or binding upon the parties unless made in writing and signed by both parties. 

  

	 	16.4	Assignment. This Agreement shall not be assignable in part or in whole by any party without the prior written consent of the other; provided, however, that either party,
without notice and at any time for any reason, may assign this Agreement in whole or in part to (i) any of its Affiliates who agree to be bound by the terms and conditions of this Agreement or (ii) any successor of such party by merger or
sale of all or substantially all of its business assets to which this Agreement relates. In the event of any such permitted assignment, the party making the assignment will remain jointly and severally liable and responsible for the performance and
observance of all its duties and obligations hereunder. 

  

	 	16.5	Notices. Any notice or other communication to be given under this Agreement, unless otherwise specified, shall be in writing and shall be deemed to have been provided when
delivered to the addressee at the address listed below (i) on the date of delivery if delivered in person or (ii) one (1) day after mailing to the other party by express mail or overnight delivery service, which obtains a signed
receipt, or (iii) three (3) days after mailing by registered or certified mail, postage paid: 

  
  
 * Portions of this document marked with **** have been
omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 23 

 In the case of ROCHE: 
 F. Hoffmann-La Roche Ltd 
 attn. Legal Department 
 Grenzacherstrasse 124 
 4070 Basel

 Switzerland 
 With a copy to:
Hoffmann-La Roche Inc. 
 attn: Corporate Secretary 
 340 Kingsland Street 
 Nutley, New Jersey 07110 
 In the case of ENS 
 Evotec Neurosciences
GmbH 
 Attn. CEO 
 Schnackenburgallee 114 
 22525 Hamburg 
 Germany 
 Either party may change its address for communications by a notice in writing to the other party
in accordance with this Section. 
  

	 	16.6	Force Majeure. Any prevention, delay or interruption of performance (collectively “Delay”) by any party under this Agreement shall not be considered a breach of
this Agreement if and to the extent caused by occurrences beyond the reasonable control of the party affected by the force majeure, including but not limited to acts of God, embargoes, governmental restrictions, general strike, fire, flood,
earthquake, explosion, riots, wars, civil disorder, rebellion or sabotage. The affected party shall immediately notify the other party upon the commencement and end of the Delay and any time for performance hereunder by both parties shall be
extended by the actual time of Delay. If the Delay resulting from the force majeure exceeds six (6) months, the other party, upon written notice to the affected party, may elect to (i) treat such Delay as a material breach, or
(ii) extend the term of this Agreement for an amount of time equal to the Delay. 

  

	 	16.7	Severability. If any term or condition of this Agreement is held by a court of competent jurisdiction to be unenforceable for any reason, it shall, if possible, be
interpreted to achieve the intent of the parties to this Agreement rather than voided. If not capable of such interpretation, the parties shall in good faith seek to agree on 

  
  
 * Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 24 

	 	 
an alternative provision reflecting the intent of the parties which is enforceable. In any event, all other terms, conditions and provision of this Agreement
shall be deemed valid and enforceable to the full extent. 

 IN WITNESS WHEREOF, the parties hereto have caused their
authorized representatives to execute this Agreement by signing below. 
 

 
 List of Annexes: 
 Compound/Roche
Patent Rights: Appendix 1 
 Roche Know-How: Appendix 2 
 Development Plan: Appendix 3 
  
  
 * Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 25 

 Appendix 1, License Agreement, **** 
 Compound/Roche Patent Rights 
  

	
	  
 APPENDIX 1
  
 GABA
  
 The product covered by the License Agreement is
  
 ****
  
 Patent Situation for ****
  

 Case ****: Product **** 
  

	 	•	 	 Priority date **** 

  

	 	•	 	 Foreign filings in **** countries, including European countries, USA and JP 

  

	 	•	 	 Expiry date **** 

 Case
****: Product **** 
  

	 	•	 	 Priority date **** 

  

	 	•	 	 Foreign filings in **** countries, including European countries, USA and JP 

  

	 	•	 	 Expiry date **** 

 Case
****: Process for preparation 
  

	 	•	 	 Priority date **** 

  

	 	•	 	 Foreign fillings in **** countries, including European countries, USA and JP, 

  

	 	•	 	 Expiry date **** 

 The main patent
case **** may be extended by national SPC’s 
 (Supplementary Patent Certificate) for 5 years. 
 Detailed information is given below: 
  
  
 * Portions of this document marked with **** have been
omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 Page 1 

 Appendix 1, License Agreement, **** 
 Compond/Roche Patent Rights 
  

					
	

	  	 ****
	  	 ****

		
	Patent Family ****	  	**** ****
			
	First Priority	  	 ****            
	  	
		
	 IDU

 (INTEGRATED DISCOVERY UNIT)
	  	CNS
		
	Family Status	  	Active
		
	Origin of Invention	  	F. Hoffmann-La Roche AG
		
	Inventors	  	 ****

		
	Title	  	 ****

		
	Abstract	  	This invention relates to ****. These compounds and salts have pronounced ****

  
  
 * Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 Page 2 

 Appendix 1, License Agreement, **** 
 Compond/Roche Patent Rights 

					
		
		  	****

  
  
 * Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 Page 3 

 Appendix 1, License Agreement, **** 
 Compound/Roche Patent Rights 
 Patent Status for **** 
 **** (Case ****) 
  

																	
	 Country
	  	 Appl. Date
	  	 Appl. No.
	  	 Grant Date
	  	 Patent No.
	  	 Expiry
	  	 Holder
	  	 Status

	 ****
	  	 ****
	  	****	  	****	  	****	  	****	  	****	  	Roche Basel	  	 ****

									
	 ****
	  	 ****
	  	****	  	****	  	****	  	****	  	****	  	Roche Basel	  	 ****

									
	 ****
	  	 ****
	  	****	  	****	  	****	  	****	  	****	  	Roche Basel	  	 ****

									
	 ****
	  	 ****
	  	****	  	****	  	****	  	****	  	****	  	Roche Basel	  	 ****

									
	 ****
	  	 ****
	  	****	  	****	  	****	  	****	  	****	  	Roche Basel	  	 ****

									
	 ****
	  	 ****
	  	****	  	****	  	****	  	****	  	****	  	Roche Basel	  	 ****

									
	 ****
	  	 ****
	  	****	  	****	  	****	  	****	  	****	  	Roche Basel	  	 ****

									
	 ****
	  	 ****
	  	****	  	****	  	****	  	****	  	****	  	Roche Basel	  	 ****

									
	 ****
	  	 ****
	  	****	  	****	  	****	  	****	  	****	  	Roche Basel	  	 ****

									
	 ****
	  	 ****
	  	****	  	****	  	****	  	****	  	****	  	Roche Basel	  	 ****

									
	 ****
	  	 ****
	  	****	  	****	  	****	  	****	  	****	  	Roche Basel	  	 ****

									
	 ****
	  	 ****
	  	****	  	****	  	****	  	****	  	****	  	Roche Basel	  	 ****

									
	 ****
	  	 ****
	  	****	  	****	  	****	  	****	  	****	  	Roche Basel	  	 ****

									
	 ****
	  	 ****
	  	****	  	****	  	****	  	****	  	****	  	Roche Basel	  	 ****

  
 *Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 Page 4 

 Appendix 1, License Agreement, **** 
 Compound/Roche Patent Rights 
  

																	
	 ****
	  	 ****
	  	****	  	****	  	****	  	****	  	****	  	Roche Basel	  	 ****

									
	 ****
	  	 ****
	  	****	  	****	  	****	  	****	  	****	  	Roche Basel	  	 ****

									
	 ****
	  	 ****
	  	****	  	****	  	****	  	****	  	****	  	Roche Basel	  	 ****

									
	 ****
	  	 ****
	  	****	  	****	  	****	  	****	  	****	  	Roche Basel	  	 ****

									
	 ****
	  	 ****
	  	****	  	****	  	****	  	****	  	****	  	Roche Basel	  	 ****

									
	 ****
	  	 ****
	  	****	  	****	  	****	  	****	  	****	  	Roche Basel	  	 ****

									
	 ****
	  	 ****
	  	****	  	****	  	****	  	****	  	****	  	Roche Basel	  	 ****

									
	 ****
	  	 ****
	  	****	  	****	  	****	  	****	  	****	  	Roche Basel	  	 ****

									
	 ****
	  	 ****
	  	****	  	****	  	****	  	****	  	****	  	Roche Basel	  	 ****

									
	 ****
	  	 ****
	  	****	  	****	  	****	  	****	  	****	  	Roche Basel	  	 ****

									
	 ****
	  	 ****
	  	****	  	****	  	****	  	****	  	****	  	Roche Basel	  	 ****

									
	 ****
	  	 ****
	  	****	  	****	  	****	  	****	  	****	  	Roche Basel	  	 ****

									
	 ****
	  	 ****
	  	****	  	****	  	****	  	****	  	****	  	Roche Basel	  	 ****

									
	 ****
	  	 ****
	  	****	  	****	  	****	  	****	  	****	  	Roche Nutley	  	 ****

  
 *Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 Page 5 

 Appendix 1, License Agreement, **** 
 Compound/Roche Patent Rights 
  

					
	

	  	APPENDIX 1	  	GABA-A
		
	Patent Family ****	  	**** ****
			
	First Priority	  	****	  	****
		
	 IDU

 (INTEGRATED DISCOVERY UNIT)
	  	CNS
		
	Family Status	  	Active
		
	Origin of Invention	  	F. Hoffman-La Roche AG
		
	Inventors	  	 ****

		
	Title	  	****
		
	Abstract	  	The present invention relates to **** and to the use of **** for the manufacture of medicaments to be used as

  
 *Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 Page 6 

 Appendix 1, License Agreement, **** 
 Compound/Roche Patent Rights 
  

					
		
		  	 **** medicaments.

  
 *Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 Page 7 

 Appendix 1, License Agreement, **** 
 Compound/Roche Patent Rights 
 Patent Status for **** 
 **** (Case ****) 
  

																	
	 Country
	  	 Appl. Date
	  	 Appl. No.
	  	 Grant Date
	  	 Patent No.
	  	 Expiry
	  	 Holder
	  	 Status

	 ****
	  	 ****
	  	****	  	****	  		  		  	****	  	Roche Basel	  	 ****

									
	 ****
	  	 ****
	  	****	  	****	  	****	  	****	  	****	  	Roche Basel	  	 ****

									
	 ****
	  	 ****
	  	****	  	****	  	****	  	****	  	****	  	Roche Basel	  	 ****

									
	 ****
	  	 ****
	  	****	  	****	  	****	  	****	  	****	  	Roche Basel	  	 ****

									
	 ****
	  	 ****
	  	****	  	****	  		  		  	****	  	Roche Basel	  	 ****

									
	 ****
	  	 ****
	  	****	  	****	  		  		  	****	  	Roche Basel	  	 ****

									
	 ****
	  	 ****
	  	****	  	****	  	****	  	****	  	****	  	Roche Basel	  	 ****

									
	 ****
	  	 ****
	  	****	  	****	  	****	  	****	  	****	  	Roche Basel	  	 ****

  
 *Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 Page 8 

 Appendix 1, License Agreement, **** 
 Compound/Roche Patent Rights 
  

																	
	 ****
	  	 ****
	  	****	  	****	  	****	  	****	  	****	  	Roche Basel	  	 ****

									
	 ****
	  	 ****
	  	****	  	****	  	****	  	****	  	****	  	Roche Basel	  	 ****

									
	 ****
	  	 ****
	  	****	  	****	  	****	  	****	  	****	  	Roche Basel	  	 ****

									
	 ****
	  	 ****
	  	****	  	****	  	****	  	****	  	****	  	Roche Basel	  	 ****

									
	 ****
	  	 ****
	  	****	  	****	  	****	  	****	  	****	  	Roche Basel	  	 ****

									
	 ****
	  	 ****
	  	****	  	****	  	****	  	****	  	****	  	Roche Basel	  	 ****

									
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	Roche Basel	  	 ****

									
	 ****
	  	 ****
	  	****	  	****	  	****	  	****	  	****	  	Roche Basel	  	 ****

									
	 ****
	  	 ****
	  	****	  	****	  	****	  	****	  	****	  	Roche Basel	  	 ****

									
	 ****
	  	 ****
	  	****	  	****	  	****	  	****	  	****	  	Roche Basel	  	 ****

									
	 ****
	  	 ****
	  	****	  	****	  	****	  	****	  	****	  	Roche Basel	  	 ****

									
	 ****
	  	 ****
	  	****	  	****	  	****	  	****	  	****	  	Roche Basel	  	 ****

									
	 ****
	  	 ****
	  	****	  	****	  	****	  	****	  	****	  	Roche Basel	  	 ****

  
 *Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 Page 9 

 Appendix 1, License Agreement, **** 
 Compound/Roche Patent Rights 
  

																	
	 ****
	  	 ****
	  	****	  	****	  	****	  	****	  	****	  	Roche Basel	  	 ****

									
	 ****
	  	 ****
	  	****	  	****	  	****	  	****	  	****	  	Roche Basel	  	 ****

									
	 ****
	  	 ****
	  	****	  	****	  	****	  	****	  	****	  	Roche Basel	  	 ****

									
	 ****
	  	 ****
	  	****	  	****	  	****	  	****	  	****	  	Roche Basel	  	 ****

									
	 ****
	  	 ****
	  	****	  	****	  	****	  	****	  	****	  	Roche Basel	  	 ****

									
	 ****
	  	 ****
	  	****	  	****	  	****	  	****	  	****	  	Roche Nutley	  	 ****

  
 *Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 Page 10 

 Appendix 1, License Agreement, **** 
 Compound/Roche Patent Rights 
  

					
	

	  	APPENDIX 1	  	GABA-A
		
	Patent Family ****	  	**** process for preparation
			
	First Priority	  	****	  	****
		
	 IDU

 (INTEGRATED DISCOVERY UNIT)
	  	CNS
		
	Family Status	  	Active
		
	Origin of Invention	  	F. Hoffman-La Roche AG
		
	Inventors	  	 ****

		
	Title	  	****
		
	Abstract	  	The present invention relates to a process for manufacturing **** carried out in the presence of **** **** ****. The **** obtained with this process are valuable intermediate
products for the manufacture of ****

  
 *Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 Page 11 

 Appendix 1, License Agreement, **** 
 Compound/Roche Patent Rights 
  

					
		
		  	 **** which show excellent psycho-pharmacological properties as agonists of the ****

  
 *Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 Page 12 

 Appendix 1, License Agreement, **** 
 Compound/Roche Patent Rights 
 Patent Status for **** 
 Process Protection (Case ****) 
  

																	
	 Country
	  	 Appl. Date
	  	 Appl. No.
	  	 Grant Date
	  	 Patent No.
	  	 Expiry
	  	 Holder
	  	 Status

	 ****
	  	 ****
	  	****	  	****	  	****	  	****	  	****	  	Roche Basel	  	 ****

									
	 ****
	  	 ****
	  	****	  	****	  	****	  	****	  	****	  	Roche Basel	  	 ****

									
	 ****
	  	 ****
	  	****	  	****	  		  		  	****	  	Roche Basel	  	 ****

									
	 ****
	  	 ****
	  	****	  	****	  		  		  	****	  	Roche Basel	  	 ****

									
	 ****
	  	 ****
	  	****	  	****	  	****	  	****	  	****	  	Roche Basel	  	 ****

									
	 ****
	  	 ****
	  	****	  	****	  	****	  	****	  	****	  	Roche Basel	  	 ****

									
	 ****
	  	 ****
	  	****	  	****	  	****	  	****	  	****	  	Roche Basel	  	 ****

									
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	Roche Basel	  	 ****

									
	 ****
	  	 ****
	  	****	  	****	  	****	  	****	  	****	  	Roche Basel	  	 ****

									
	 ****
	  	 ****
	  	****	  	****	  	****	  	****	  	****	  	Roche Basel	  	 ****

									
	 ****
	  	 ****
	  	****	  	****	  	****	  	****	  	****	  	Roche Basel	  	 ****

									
	 ****
	  	 ****
	  	****	  	****	  		  	****	  	****	  	Roche Basel	  	 ****

									
	 ****
	  	 ****
	  	****	  	****	  	****	  	****	  	****	  	Roche Basel	  	 ****

									
	 ****
	  	 ****
	  	****	  	****	  	****	  	****	  	****	  	Roche Basel	  	 ****

									
	 ****
	  	 ****
	  	****	  	****	  		  		  	****	  	Roche Basel	  	 ****

  
 *Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 Page 13 

 Appendix 1, License Agreement, **** 
 Compound/Roche Patent Rights 
  

																	
	 ****
	  	 ****
	  	****	  	****	  	****	  	****	  	****	  	Roche Basel	  	 ****

									
	 ****
	  	 ****
	  	****	  	****	  	****	  	****	  	****	  	Roche Basel	  	 ****

									
	 ****
	  	 ****
	  	****	  	****	  	****	  	****	  	****	  	Roche Basel	  	 ****

									
	 ****
	  	 ****
	  	****	  	****	  	****	  	****	  	****	  	Roche Nutley	  	 ****

  
 *Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 Page 14 

 Appendix 2, License Agreement, ****, 
 Roche Know-How 
 Appendix 2 
 Roche Know-Know 
  

																									
	 Hlt
	  	Rank	  	 Title
	  	Document Date	  	 Library
	  	Report No	 	 Main Author
	  	 Document
	  	MF ID	  	Date Submit	  	 Substance ID
	  	Pages	  	Date Approved
	 1
	  	100	  	****	  	22.02.2000	  	Regulatory Document	  	****	 	****	  	regular	  	1E+06	  	29.03.2000	  	****	  	33	  	29.03.2000
	 2
	  	100	  	****	  	29.11.1999	  	Regulatory Document	  	****	 	****	  	regular	  	1E+06	  	14.02.2000	  	****	  	57	  	14.02.2000
	 3
	  	100	  	****	  	22.12.1999	  	Regulatory Document	  	****	 	****	  	regular	  	1E+06	  	02.02.2000	  	****	  	39	  	02.02.2000
	 4
	  	100	  	****	  	06.07.2000	  	Regulatory Document	  	****	 	****	  	regular	  	2E+06	  	18.07.2000	  	****	  	131	  	18.07.2000
	 5
	  	100	  	****	  	07.06.2000	  	Regulatory Document	  	****	 	****	  	regular	  	1E+06	  	03.07.2000	  	****	  	82	  	03.07.2000
	 6
	  	100	  	****	  	07.06.2000	  	Regulatory Document	  	****	 	****	  	regular	  	1E+06	  	03.07.2000	  	****	  	54	  	03.07.2000
	 7
	  	100	  	****	  	07.06.2000	  	Regulatory Document	  	****	 	****	  	regular	  	1E+06	  	03.07.2000	  	****	  	85	  	03.07.2000

  
 *Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 1 

 Appendix 2, License Agreement, ****, 
 Roche Know-How 
  

																									
	 8
	  	100	  	****	  	07.06.2000	  	Regulatory Document	  	****	 	****	  	regular	  	1E+06	  	03.07.2000	  	****	  	84	  	03.07.2000
	 9
	  	100	  	****	  	07.06.2000	  	Regulatory Document	  	****	 	****	  	regular	  	1E+06	  	03.07.2000	  	****	  	118	  	03.07.2000
	 10
	  	100	  	****	  	21.04.1999	  	Regulatory Document	  	****	 	****	  	regular	  	59893	  	05.05.1999	  	****	  	47	  	05.05.1999
	 11
	  	100	  	****	  	21.04.1999	  	Regulatory Document	  	****	 	****	  	regular	  	59892	  	05.05.1999	  	****	  	44	  	05.05.1999
	 12
	  	100	  	****	  	12.03.1999	  	Regulatory Document	  	****	 	****	  	regular	  	59768	  	15.04.1999	  	****	  	25	  	15.04.1999
	 13
	  	100	  	****	  	15.02.1999	  	Regulatory Document	  	****	 	****	  	regular	  	59612	  	26.03.1999	  	****	  	51	  	26.03.1999
	 14
	  	100	  	****	  	17.11.1998	  	Regulatory Document	  	****	 	****	  	regular	  	59320	  	26.02.1999	  	****	  	35	  	26.02.1999
	 15
	  	100	  	****	  	20.11.1998	  	Regulatory Document	  	****	 	****	  	regular	  	59034	  	05.01.1999	  	****	  	36	  	05.01.1999
	 16
	  	100	  	****	  	27.10.1998	  	Regulatory Document	  	****	 	****	  	regular	  	58516	  	09.11.1998	  	****	  	25	  	09.11.1998

  
 *Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 2 

 Appendix 2, License Agreement, ****, 
 Roche Know-How 
  

																									
	 17
	  	100	  	****	  	23.03.2000	  	Regulatory Document	  	****	 	****	  	regular	  	1E+06	  	14.04.2000	  	****	  	190	  	14.04.2000
	 18
	  	100	  	****	  	22.03.2000	  	Regulatory Document	  	****	 	****	  	regular	  	1E+06	  	13.04.2000	  	****	  	161	  	13.04.2000
	 19
	  	100	  	****	  	26.08.1999	  	Regulatory Document	  	****	 	****	  	regular	  	1E+06	  	19.10.1999	  	****	  	28	  	19.10.1999
	 20
	  	100	  	****	  	30.06.1999	  	Regulatory Document	  	****	 	****	  	regular	  	1E+06	  	14.10.1999	  	****	  	56	  	14.10.1999
	 21
	  	100	  	****	  	16.07.1999	  	Regulatory Document	  	****	 	****	  	regular	  	1E+06	  	29.07.1999	  	****	  	28	  	29.07.1999
	 22
	  	100	  	****	  	22.06.1999	  	Regulatory Document	  	****	 	****	  	regular	  	1E+06	  	12.07.1999	  	****	  	25	  	12.07.1999
	 23
	  	100	  	****	  	11.05.1999	  	Regulatory Document	  	****	 	****	  	regular	  	1E+06	  	21.06.1999	  	****	  	64	  	21.06.1999
	 24
	  	100	  	****	  	27.04.1999	  	Regulatory Document	  	****	 	****	  	regular	  	1E+06	  	10.06.1999	  	****	  	26	  	10.06.1999
	 25
	  	100	  	****	  	16.03.2001	  	Regulatory Document	  	****	 	****	  	regular	  	2E+06	  	01.06.2001	  	****	  	1067	  	01.06.2001

  
 *Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 3 

 Appendix 2, License Agreement, ****, 
 Roche Know-How 
  

																									
	 26
	  	100	  	****	  	25.10.2000	  	Regulatory Document	  	****	 	****	  	regular	  	2E+06	  	29.11.2000	  	****	  	63	  	06.02.2001
	 27
	  	100	  	****	  	25.10.2000	  	Regulatory Document	  	****	 	****	  	regular	  	2E+06	  	16.01.2001	  	****	  	137	  	16.01.2001
	 28
	  	100	  	****	  	07.12.2000	  	Regulatory Document	  	****	 	****	  	regular	  	2E+06	  	27.02.2001	  	****	  	30	  	28.02.2001
	 29
	  	100	  	****	  	07.02.2000	  	Research Project	  	****	 	****	  	research	  	1E+06	  	30.03.2000	  	****	  	36	  	30.03.2000
	 30
	  	100	  	****	  	23.12.1999	  	Research Project	  	****	 	****	  	research	  	1E+06	  	17.03.2000	  	****	  	31	  	17.03.2000
	 31
	  	100	  	****	  	22.11.1999	  	Research Project	  	****	 	****	  	research	  	1E+06	  	28.01.2000	  	****	  	28	  	28.01.2000
	 32
	  	100	  	****	  	13.12.1999	  	Research Project	  	****	 	****	  	research	  	1E+06	  	06.01.2000	  	****	  	35	  	06.01.2000
	 33
	  	100	  	****	  	10.12.1999	  	Research Project	  	****	 	****	  	research	  	1E+06	  	06.01.2000	  	****	  	47	  	06.01.2000
	 34
	  	100	  	****	  	29.11.1999	  	Research Project	  	****	 	****	  	research	  	1E+06	  	06.01.2000	  	****	  	47	  	06.01.2000

  
 *Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 4 

 Appendix 2, License Agreement, ****, 
 Roche Know-How 
  

																									
	 35
	  	100	  	****	  	10.12.1999	  	Research Project	  	****	 	****	  	research	  	1E+06	  	06.01.2000	  	****	  	36	  	06.01.2000
	 36
	  	100	  	****	  	15.12.1999	  	Research Project	  	****	 	****	  	research	  	1E+06	  	06.01.2000	  	****	  	29	  	06.01.2000
	 37
	  	100	  	****	  	07.12.1999	  	Research Project	  	****	 	****	  	research	  	1E+06	  	05.01.2000	  	****	  	32	  	05.01.2000
	 38
	  	100	  	****	  	23.11.1999	  	Research Project	  	****	 	****	  	research	  	1E+06	  	27.12.1999	  	****	  	24	  	27.12.1999
	 39
	  	100	  	****	  	15.11.1999	  	Research Project	  	****	 	****	  	research	  	1E+06	  	22.12.1999	  	****	  	71	  	22.12.1999
	 40
	  	100	  	****	  	09.12.1999	  	Research Project	  	****	 	****	  	research	  	1E+06	  	22.12.1999	  	****	  	39	  	22.12.1999
	 41
	  	100	  	****	  	13.04.1999	  	Regulatory Document	  	****	 	****	  	regular	  	59816	  	18.03.1999	  	****	  	57	  	18.03.1999
	 42
	  	99	  	****	  	25.01.1999	  	Regulatory Document	  	****	 	****	  	regular	  	59223	  	03.02.1999	  	****	  	20	  	03.02.1999
	 43
	  	99	  	****	  	25.10.2000	  	Regulatory Document	  	****	 	****	  	regular	  	2E+06	  	29.11.2000	  	****	  	42	  	06.02.2001
	 44
	  	98	  	****	  	24.08.2000	  	Regulatory Document	  	****	 	****	  	regular	  	2E+06	  	09.10.2000	  	****	  	102	  	09.10.2000

  
 *Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 5 

 Appendix 2, License Agreement, ****, 
 Roche Know-How 
  

																									
	 45
	  	97	  	****	  	25.10.2000	  	Regulatory Document	  	****	 	****	  	regular	  	2E+06	  	29.11.2000	  	****	  	43	  	06.02.2001
	 46
	  	97	  	****	  	01.07.1999	  	Regulatory Document	  	****	 	****	  	regular	  	1E+06	  	13.09.1999	  	****	  	29	  	13.09.1999
	 47
	  	97	  	****	  	23.10.1997	  	Research Project	  	****	 	****	  	research	  	58504	  	18.12.1997	  	****	  	17	  	18.12.1997
	 48
	  	96	  	****	  	18.01.2000	  	Research Project	  	****	 	****	  	research	  	1E+06	  	03.02.2000	  	****	  	18	  	03.02.2000
	 49
	  	96	  	****	  	01.03.2000	  	Research Project	  	****	 	****	  	research	  	1E+06	  	23.05.2000	  	****	  	28	  	23.05.2000
	 50
	  	95	  	****	  	05.08.1999	  	Regulatory Document	  	****	 	****	  	regular	  	1E+06	  	20.10.1999	  	****	  	54	  	20.10.1999
	 51
	  	95	  	****	  	15.10.1998	  	Research Project	  	****	 	****	  	research	  	58618	  	30.10.1998	  	****	  	23	  	30.10.1998
	 52
	  	93	  	****	  	05.01.1998	  	Research Project	  	****	 	****	  	research	  	56688	  	29.01.1998	  	****	  	17	  	29.01.1998
	 53
	  	91	  	****	  	16.04.1999	  	Regulatory Document	  	****	 	****	  	regular	  	1E+06	  	27.01.1999	  	****	  	16	  	27.01.1999
	 54
	  	90	  	****	  	28.07.1999	  	Regulatory Document	  	****	 	****	  	regular	  	1E+06	  	16.11.1999	  	****	  	12	  	16.11.1999
	 55
	  	88	  	****	  	23.11.1999	  	Research Project	  	****	 	****	  	research	  	1E+06	  	10.12.1999	  	****	  	29	  	10.12.1999
	 56
	  	87	  	****	  	11.01.1999	  	Research Project	  	****	 	****	  	research	  	59300	  	17.02.1999	  	****	  	32	  	17.02.1999

  
 *Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 6 

 Appendix 2, License Agreement, ****, 
 Roche Know-How 
  

																									
	 57
	  	86	  	****	  	20.07.1999	  	Research Project	  	****	 	****	  	research	  	1E+06	  	05.08.1999	  	****	  	83	  	05.08.1999
	 58
	  	85	  	****	  	22.05.2000	  	Research Project	  	****	 	****	  	research	  	1E+06	  	13.06.2000	  	****	  	99	  	13.06.2000
	 59
	  	83	  	****	  	03.07.1998	  	Regulatory Document	  	****	 	****	  	regular	  	57917	  	18.08.1998	  	****	  	37	  	18.08.1998
	 60
	  	81	  	****	  	07.06.2000	  	Regulatory Document	  	****	 	****	  	regular	  	1E+06	  	03.07.2000	  	****	  	94	  	03.07.2000
	 61
	  	81	  	****	  	07.06.2000	  	Regulatory Document	  	****	 	****	  	regular	  	1E+06	  	03.07.2000	  	****	  	92	  	03.07.2000
	 62
	  	81	  	****	  	26.06.1998	  	Research Project	  	****	 	****	  	research	  	58051	  	01.09.1998	  	****	  	82	  	01.09.1998
	 63
	  	80	  	****	  	08.08.2000	  	Research Project	  	****	 	****	  	research	  	2E+06	  	09.10.2000	  	****	  	45	  	09.10.2000

  
 *Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 7 

 Appendix 3, License Agreement, ****, Development Plan 
 Appendix 3 
 Development Plan for an oral GABA antagonist (****) 
 Compound Supply 
 Lot # **** 1 - 13. Nov. 1998 - ****, approx. 35g on
stock, milled 
 Lot # **** 1 - 29. Jul. 1999 - ****, approx. 3.447kg on stock, milled 
 Lot # **** 1 - Aug. 1999 - **** , ca. approx. 0.859kg on stock (Non-GMP), milled 
 Purification of above listed lots and
synthesis of additional cGMP Kg quantities required for phase II studies will be done by EOAI. 
 Phase II studies 
 Dose finding study followed by Proof-of-Concept studies for sleep induction and sleep maintenance. 
 Potential scenarios include: 
  

	1.	Dose finding studies. Double-blind, placebo controlled, ~10 patients (insomniacs or volunteers) per arm. 4 dose levels. 

 Outcome measures: Efficacy (sleep induction and maintenance) and side effects (hang over effects, other side effects). 
  

	2.	Proof-of-Concept study in man. Repeated dose, 2 dose levels, double-blind, placebo controlled trail, 50 to 100 patients (insomniacs) per arm. 

 Outcome measures: Efficacy (sleep induction and maintenance, quality of sleep) side effects (hang over effects, tolerance, dependence) 
 Timeline: 
 Dose finding – Start Q2 2006, expected duration
approximately 4 months 
 Proof of concept – Start Q4 2006/Q1 2007, expected duration 12 to 18 months 
  
 *Portions of this document marked with **** have been
omitted pursuant to a request for confidential treatment submitted with the SEC.License Agreement, dated January 6, 2006

 Exhibit 10.4 
 License Agreement 
 This Agreement is entered into on the Effective Date (as defined below) by and 
 between 
 F. Hoffmann-La Roche Ltd 
 with an office and place of business at Grenzacherstr.124, CH-4070 Basel, Switzerland (“ROCHE Basel”) 
 and 
 Hoffmann-La Roche Inc. 
 with an office and place of business at 340 Kingsland Street, Nutley, NJ 07110, USA (“ROCHE Nutley”; ROCHE Basel and ROCHE Nutley together referred to as
“ROCHE”) 
 on the one hand 
 and 
 Evotec Neurosciences GmbH, Schnackenburgallee 114, 22525 Hamburg, Germany (“EVOTEC”) 
 on the other hand 
 WHEREAS, ROCHE is the owner of certain patent rights and know-how relating to the
Compound (as defined below); and 
 WHEREAS, EVOTEC wishes to perform certain development work with respect to the Compound with the purpose
of filing an NDA or equivalent in other countries in order to obtain marketing approval in the Territory and to subsequently market the Product; and 
  
  
 * Portions of this document marked with **** have been
omitted pursuant to a request for confidential treatment submitted with the SEC. 

 WHEREAS, EVOTEC wishes to obtain, and ROCHE wishes to grant rights and licenses under the ROCHE Patent
Rights and ROCHE Know-How (as defined below); and 
 Whereas, EVOTEC considers ROCHE a preferred partner for both development and
commercialization. This is based on the general capabilities of ROCHE, the fact that EVOTEC currently has two programs in-licensed from ROCHE as well as the fact that the companies have a long standing and productive service based relationship.

 NOW, THEREFORE, in consideration of the mutual promises and covenants contained in this Agreement, the parties agree as follows:

  

	1.	Definitions 

  

	 	1.1.	“Affiliate” shall mean with respect to either party (i) an entity which owns, directly or indirectly, a controlling interest in such party, by stock ownership
or otherwise; or (ii) an entity which is owned by such party, either directly or indirectly, by stock ownership or otherwise; or (iii) an entity, the majority ownership of which is directly or indirectly common to the majority ownership of
such party. Anything to the contrary in this paragraph notwithstanding, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080-4990, U.S.A. and Chugai Pharmaceutical Co., Ltd, Nihonbashi-Muromachi 2-chome, Chuo-ku, Tokyo, 103-832, Japan
(“Chugai”) shall not be deemed an Affiliate of ROCHE unless ROCHE notifies EVOTEC that ROCHE wishes for Genentech, Inc. and/or Chugai Pharmaceutical Co., Ltd, to be deemed an Affiliate of ROCHE. 

  

	 	1.2.	“Commercialisation Option” shall mean ROCHE’s commercialisation option right to take back a Compound in the Field at the End of Phase III as set forth in
Section 4.2. 

  

	 	1.3.	“Commercially Reasonable Efforts” shall mean those efforts, activities and measures, which a diligent Third Party company active in a similar field as the
respective party, would consider to be commercially reasonable, feasible and viable to be performed, undertaken or made in or under the specific circumstances. 

  

	 	1.4.	“Completion” shall mean the final study report for a respective study. 

  

  
 * Portions of this document marked with
**** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 2 

	 	1.5.	“Compound” shall mean **** and **** specified in Appendix 1. 

  

	 	1.6.	“Confidential Information” shall mean any and all information, data or know-how, whether technical or non-technical, oral or written, related to the Compound
and the Product that is disclosed by one party or its Affiliates (“Disclosing Party”) to the other party or its Affiliates (“Receiving Party”). Confidential Information shall not include any information, data or know-how which:

  

	 	1.6.1.	either before or after disclosure to the Receiving Party, was or becomes published or generally known to the public through no fault or omission on the part of the Receiving Party;
or 

  

	 	1.6.2.	was known or used by the Receiving Party prior to its disclosure by the Disclosing Party to the Receiving Party; or 

  

	 	1.6.3.	either before or after disclosure to the Receiving Party, is provided to the Receiving Party by a Third Party having the right to do so; 

  

	 	1.6.4.	is independently developed by the Receiving Party without reference to any Confidential Information previously disclosed by the Disclosing Party; or 

  

	 	1.6.5.	is required to be disclosed by the Receiving Party to comply with applicable laws, to defend or prosecute litigation or to comply with governmental regulations, provided that, the
Receiving Party provides prior written notice of such disclosure to the Disclosing Party and, to the extent practicable, requests confidential treatment (where available) or takes reasonable and lawful actions to minimize the degree of such
disclosure. 

  

	 	1.7.	“Development Plan” shall mean the EVOTEC Development Plan attached to this Agreement as Appendix 3. The Development Plan shall include a development plan for all
Compounds developed by EVOTEC under this Agreement. 

  

	 	1.8.	“Effective Date” shall mean January 6, 2006. 

  

	 	1.9.	“End of Phase IIb” shall mean Completion of the last Phase II study providing Proof of Concept. 

  
  
 * Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 3 

	 	1.10.	“End of Phase III” shall mean Completion of the last Phase III study. 

  

	 	1.11.	“EVOTEC Patent Rights and Know-How” shall mean all information, data and know-how, improvements, inventions, discoveries and other technology, whether or not
patentable, made or developed by or on behalf of EVOTEC in the course of its activities pursuant to this Agreement, which relate to a Compound or Product, and any patents, patent applications, or other intellectual property rights based on the
foregoing (“EVOTEC Patent Rights”), including, by way of example only, all divisionals, continuations, continuations-in-part, re-examinations, reissues, extensions, registrations, confirmations and supplementary or complementary
certificates and the like with respect to any of the foregoing. 

  

	 	1.12.	“FDA” shall mean the U.S. Federal Food and Drug Administration and any successor agency thereof. 

  

	 	1.13.	“Field” shall mean the treatment and/or prevention of any indication in humans. 

  

	 	1.14.	“First Commercial Sale” shall mean the first invoiced sale of a Product by EVOTEC or its respective Affiliates or Sublicensees. 

  

	 	1.15.	“Development Option” shall mean ROCHE’s first option right to take back a Compound in the Field at the End of Phase IIb as set forth in Section 4.1.

  

	 	1.16.	“Marketing Authorization” shall mean such governmental approval (including pricing approval, where required) for the marketing of a Product in a country of the
Territory as is necessary to enable sale and distribution of the Product in such country, which approval results from an NDA Filing or an equivalent filing. 

  

	 	1.17.	“NDA Filing” shall mean a New Drug Application filed as a result of activities under this Agreement with the FDA, or the equivalent application to the equivalent
agency in any other country of the Territory, the filing of which is necessary to market and sell a Product, including all amendments and supplements to any of the foregoing. 

  

	 	1.18.	“ Net Sales” and the related term “Adjusted Gross Sales” shall mean for either party distributing and selling Product (in this Section the
“Selling Party”): 

  

	 	1.18.1.	Adjusted Gross Sales shall mean the gross sales of Products as invoiced by the Selling Party or its Affiliates and Sublicensees to Third Parties, less

  
  
 * Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 4 

	 	 
deductions for returns (including withdrawals and recalls), rebates (price reductions including Medicaid and similar types of rebates, e.g. chargebacks),
volume (quantity) discounts granted at the time of invoicing, sales taxes and other taxes directly linked and included in the gross sales amount (with respect to ROCHE as computed in the central ROCHE Swiss Francs Sales Statistics) for the countries
concerned in accordance with the Selling Party’s then current standard practices, whereby the amount of such sales in foreign currencies is converted into CHF or Euros, as applicable. 

  

	 	1.18.2.	Net Sales shall mean the amount calculated by subtracting from Adjusted Gross Sales a lump sum deduction of **** of Adjusted Gross Sales for those sales-related deductions
that are not accounted for on a product-by-product basis (e.g. outward freights, postage, transportation insurance, packing materials for dispatch of goods, custom duties, discounts granted later than at the time of invoicing, cash discounts and
other direct expenses). 

  

	 	1.19.	“Other Indications” shall mean all indications other than ****. 

  

	 	1.20.	“Phase II Initiation” shall mean the date of first administration of Product to a patient in a second phase of human clinical trials required by the FDA to gain
evidence of efficacy of Product in a target population, determine optimal dosage, and to obtain expanded evidence of safety for Product, as described in 21 CFR Part 312(c), as it may be amended (or its successor regulation).

  

	 	1.21.	“Phase III Initiation” shall mean the date of first administration of Product to a patient in a third phase of human clinical trials required by the FDA to gain
evidence of efficacy of Product in a target population, and to obtain expanded evidence of safety for Product that is needed to evaluate the overall benefit-risk relationship of Product and provide an adequate basis for physician labeling, as
described in 21 CFR Part 312(c), as it may be amended (or its successor regulation). 

  

	 	1.22.	“Product” shall mean any pharmaceutical dosage form that includes a Compound as active pharmaceutical ingredient. 

  

	 	1.23.	“Proof of Concept” shall mean evidence that the effect in the mechanism leads to a desired short-term clinical outcome. 

  
  
 * Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 5 

	 	1.24.	“ROCHE Know-How” shall mean the ROCHE information and data including but not limited to notes, correspondence, certificates, results and official correspondence
specified in Appendix 2. 

  

	 	1.25.	“ROCHE Patent Rights” shall mean the patent applications and patents listed in Appendix 1, including, by way of example only, all divisionals, continuations,
continuations-in-part, re-examinations, reissues, extensions, registrations, confirmations and supplementary or complementary certificates and the like with respect to any of the foregoing. 

  

	 	1.26.	“Royalty Term” shall mean, with respect to each Product in each country, the period of time commencing on the First Commercial Sale of such Product in such country
and ending on the later of the date that is (a) 10(ten) years after the date of the First Commercial Sale of such Product in such country, and (b) the expiration of the last to expire Valid Patent Claim in such country claiming the
manufacture, use, import, offering for sale, or sale of such Product. With regard to the calculation of the 10(ten) year period, the EU shall be considered as one country. 

  

	 	1.27.	“Sublicensee” shall mean any Third Party to which Evotec grants any rights to develop and/or commercialise the Compounds and/or Products under this Agreement,
including but not limited to exclusive sublicenses, co-promotion.rights, etc. “Sublicensed” shall mean the activity of granting rights to a Sublicensee. 

  

	 	1.28.	“Territory” shall mean all countries and territories of the world. 

  

	 	1.29.	“Third Party” shall mean an entity other than a party to this Agreement and its respective Affiliates, if any. 

  

	 	1.30.	“Valid Patent Claim” shall mean (a) unexpired ROCHE Patent Right (including inventor’s certificates) in any country of the Territory that have not been
held invalid or unenforceable by a court of competent jurisdiction from which no appeal can be taken or has been taken within the required time period, including without limitation any substitution, extension, term restoration, registration,
confirmation, reissue, re-examination, renewal or any like filing thereof and (b) pending applications for a ROCHE Patent Right in any country of the Territory, including without limitation any continuation, division or continuation-in-part
thereof and any provisional applications. 

  

	 	1.31.	In the definitions, the singular shall include the plural and vice versa. 

  
  
 * Portions of this document marked with **** have been
omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 6 

	2.	Grant of Rights 

  

	 	2.1.	License Grant. ROCHE Nutley for the US territory and ROCHE Basel for the rest of the Territory (other than the US territory) hereby grant to EVOTEC a worldwide, exclusive
(even as to Roche) right and license to develop, to make, have made, use, offer for sale, sell and import Compounds and Products in the Territory in the Field, under the ROCHE Patent Rights and the ROCHE Know-How. 

  

	 	2.2.	Right to Sublicense. EVOTEC shall have the right to sublicense its rights under Section 2.1. after the expiry of the Development Option. Any sub-license agreements shall
be subject to Roche’s rights under this Agreement. Evotec shall inform Roche reasonably in advance before entering into a sub-license agreement with a Third Party and seek Roche’s advice. If Evotec grants such a sublicense, Evotec shall
ensure that all of the applicable terms and conditions of this Agreement shall apply to the Affiliate or Third Party Sublicensee to the same extent as they apply to Evotec for all purposes. Evotec assumes full responsibility for the performance of
all obligations so imposed on such Affiliate or Third Party Sublicensee and will itself account to Roche for all payments due under this Agreement by reason of such sublicense. 

  

	3.	Transfer of ROCHE Know-How 

  

	 	3.1.	Transfer of ROCHE Know-How. Immediately after Effective Date, Roche shall start to provide to EVOTEC the ROCHE KNOW-HOW listed in Appendix 2. The transfer of Roche Know-How
shall be completed within six (6) months after Effective Date. 

  

	 	3.2.	Access to ROCHE Know-How. During the Term of this Agreement, ROCHE shall at all times have full access to the ROCHE Know-How. 

  

	 	3.3.	Supply of Compounds. 

  

	 	3.3.1.	Upon request of EVOTEC by December 31, 2006, ROCHE shall supply to EVOTEC free of charge, to the extent available and existing, up to 5 gr reference sample of Compounds for
research purposes. 

  
  
 * Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 7 

	 	3.3.2.	Upon request of EVOTEC by December 31, 2006, ROCHE shall supply to EVOTEC existing and available quantities of API and drug product for clinical development purposes at the
following prices: 

 a) Up to 135 kg of GMP API material, useable for clinical supply, at price of 15,000 CHF per Kg; and

 b) Up to 983.6 kg of FOM-Ether, at a price of 500 CHF per Kg; and 
 c) Up to 10 mg capsule approx. 190,000 units, at a price of 0.315 CHF per capsule; and 
 d) Up to 25 mg capsule approx. 270,000 units, at a price of 0.78 CHF per capsule. 
 If Roche has further stock of material, the parties shall enter into good faith discussions regarding the transfer of such stock by December 31,
2006 against a reasonable compensation. 
 However, the supply of Compounds under this Section 3.3. shall be limited to the Compounds
existing and available at ROCHE. ROCHE gives no warranty as to purity or quality of the Compounds, which are transferred in current state only. ROCHE shall have no obligation to perform any work related to the Compounds (e.g. research, development,
manufacturing work) for EVOTEC. 
  

	4.	Option rights of ROCHE. 

  

	 	4.1.	Development Option at the End of Phase IIb 

  

	 	4.1.1.	Evotec shall provide to Roche a pre-notification that the End of Phase IIb Notice will occur at least thirty (30) days before such anticipated End of Phase IIb.

  

	 	4.1.2.	Promptly after a Compound has reached the End of Phase IIb, EVOTEC shall notify ROCHE in writing (“End of Phase IIb Notice”). The End of Phase IIb Notice shall include (i)
an executive summary report on the development of the Compound in question, (ii) all data 

  
  
 * Portions of this document marked with **** have been
omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 8 

	 	and all information on the development including detailed Phase IIb results for each indication, including a written development report, and (iii) a list of any EVOTEC Patent Rights
and Know-How for the Compound in question up to such date. 

  

	 	4.1.3.	Commencing on the date of the End of Phase IIb Notice and for a period of ninety (90) days thereafter (“End of Phase IIb Negotiation Period”), the parties shall promptly
enter into serious good faith negotiations concerning an exclusive right (even as to EVOTEC) for Roche from EVOTEC in the Territory to make, have made, use, offer for sale, sell and/or import the Compound in question and corresponding Products in
the Field, under the EVOTEC Patent Rights and Know-How. The financial terms shall be based on benchmark market terms taking into consideration the potential value (including without limitation the taking back of the license granted in Section 2 as
outlined in Section 4.1.3 below) , and the scope of the patent rights. 

 If, during the End of Phase IIb Negotiation Period,
Roche decides that it is not interested in entering a discussion to take back the Products, it will inform Evotec of such decision without undue delay. 
 Upon an agreement entered between the parties following the negotiations mentioned under 4.1.3, (i) the rights and obligations of EVOTEC set forth in Sections 2.1., 2.2., and 5 relating to the Compound in question and
the obligation of EVOTEC to pay milestone payments as per Section 7.1. not yet due relating to the Compound in question shall terminate as of even date and (ii) ROCHE shall have an exclusive right and license (even as to EVOTEC) with the right to
sub-license from EVOTEC in the Territory to make, have made, use, offer for sale, sell and/or import the Compound in question and corresponding Products in the Field, under the EVOTEC Patent Rights and Know-How. 
  

	 	4.1.4.	If the parties do not reach an agreement on the essential terms in a detailed term sheet during the End of Phase IIb Negotiation Period, then EVOTEC shall be free to develop the
Compound in question as foreseen under this Agreement and/or to grant sub-license(s) and/or 

  
  
 * Portions of this document marked with **** have been
omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 9 

	 	enter into co-development or co-marketing arrangement(s) with any Third Party, subject to Roche’s rights under Section 4.2.2. 

  

	 	4.1.5.	If Initiation of Phase II has not occurred for at least one Compound within three (3) years after the Effective Date then ROCHE shall have the right to take back the license at no
cost. 

  

	 	4.2.	Commercialisation Option at the End of Phase III 

  

	 	4.2.1.	EVOTEC shall provide to Roche a pre-notification that the End of Phase III Notice will occur at least thirty (30) days before such anticipated End of Phase III.

  

	 	4.2.2.	Insofar as EVOTEC has not transferred complete control of commercialization rights via an arrangement as outlined in Section 4.1.4 above, but has retained full or partial control of
commercialisation rights, e.g. via (i) commercialization by EVOTEC and a financing vehicle, (ii) EVOTEC retaining regional commercialization rights or (iii) EVOTEC having entered into a co-commercialisation agreement with a third party, then
promptly after a Compound has reached the End of Phase III, EVOTEC shall notify ROCHE in writing (“End of Phase III Notice”). The End of Phase III Notice shall include (i) Proof of Concept, (ii) an executive summary report on the
development of the Compound in question, (iii) all data and all information on the development including but not limited to detailed Phase II and Phase III results, including a written development report, and (iv) a list of any EVOTEC Patent Rights
and Know-How for the Compound in question up to such date. 

  

	 	4.2.3.	Commencing on the date of the End of Phase III Notice and for a period of ninety (90) days thereafter (“End of Phase III Negotiation Period”), the parties shall promptly
enter into serious good faith negotiations concerning a right for Roche from EVOTEC with regard to the commercialization rights still retained by Evotec to make, have made, use, offer for sale, sell and/or import the Compound in question and
corresponding Products in the Field, under the EVOTEC Patent Rights and Know-How. For clarity, if EVOTEC has transferred complete control of commercialization rights via an arrangement as 

  
  
 * Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 10 

  

	 	outlined in Section 4.1.4 above, then EVOTEC and the respective Sublicensee shall be free of any obligation to enter into such negotiations with ROCHE concerning such
commerzialisation. ROCHE may exercise such option by providing to EVOTEC written notice during the End of Phase III Option Period. The financial terms shall be based on benchmark market terms taking into consideration the potential value (including
without limitation the taking back of the license granted in Section 2 as outlined in Section 4.2.4), and the scope of the patent rights. 

  

	 	4.2.4.	Insofar as EVOTEC has retained control of commercialization rights as outlined in Section 4.2.2 above and upon an agreement entered between the parties following the negotiations
mentioned under 4.2.2, (i) the rights and obligations of EVOTEC set forth in Sections 2.1., 2.2., and 5. relating to the Compound in question and the obligation of EVOTEC to pay milestone payments as per Section 7.1. not yet due relating to the
Compound in question shall terminate as of even date and (ii) ROCHE shall have an exclusive right and license (even as to EVOTEC) with the right to sub-license from EVOTEC in the Territory, to make, have made, use, offer for sale, sell and/or import
the Compound in question and corresponding Products in the Field, under the EVOTEC Patent Rights and Know-How. 

  

	 	4.2.5.	If the parties do not reach an agreement on the essential terms in a detailed term sheet of during the End of Phase III Negotiation Period, then Roche’s rights under this
Section 4.2 shall lapse with respect to the Compound in question. 

  

	 	4.2.6.	If, during the End of Phase III Negotiation Period, Roche decides that it is not interested in entering a discussion to take back the Products, it will inform Evotec of such
decision without undue delay. 

  

	 	4.2.7.	If Phase III Initiation has not occurred for at least one Compound within two (2) years after the Completion of Phase II for such Compound, then ROCHE will have the right to take
back the license at no cost. 

  
  
 * Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 11 

	5.	Diligence 

  

	 	5.1.	EVOTEC Diligence and Reporting.  

  

	 	5.1.1.	At all times during the term of this Agreement, EVOTEC will use and will cause its Affiliates and Sublicensees to use Commercially Reasonable Efforts to proceed with the
development, manufacture, marketing, distribution and sale of at least one Compound and/or Product. At least one Compound will be primarily developed in ****. 

  

	 	5.1.2.	During the term of this Agreement, at each anniversary of the Effective Date, EVOTEC shall provide ROCHE with 

 a) a written summary report on the status of development of the Compound; 
 b) an updated version of the Development Plan which shall be deemed to be attached as revised Appendix 3. 
 c) all approvals received by EVOTEC, its Affiliates and sub-licensees (if any). 
 EVOTEC shall supplement such written documents as
reasonably requested by ROCHE, but shall have no obligation to make such supplements more than twice in any calendar year. 
 The parties
will favorably consider yearly meetings in person to discuss the status of development of the Compounds. 
  

	 	5.1.3.	If ROCHE reasonably believes that EVOTEC is not using Commercially Reasonable Efforts with respect to the development or commercialization of the Compound, then ROCHE may provide
EVOTEC written notice specifying in reasonable detail the reasons why ROCHE believes that EVOTEC is not using Commercially Reasonable Efforts with respect to the Compound. Upon receipt of such notice, EVOTEC shall have a period of ninety
(90) days to present evidence to ROCHE that EVOTEC is using Commercially Reasonable Efforts with respect to the Compound or to cure the lack of diligence based on the reasons submitted by ROCHE (“Evidence and Cure Period”). If EVOTEC
presents 

  
  
 * Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 12 

	 	    	evidence reasonably acceptable to ROCHE, then ROCHE’s notice shall be deemed withdrawn and of no effect. If, within such period, EVOTEC has not presented evidence reasonably
acceptable to demonstrate that EVOTEC has used Commercially Reasonable Efforts to develop the Compound and has not cured such lack of diligence within such period, then ROCHE shall have the right to terminate this Agreement for the Compound in
question with immediate effect and Section 13. shall apply. 

  

	6.	Down Payments. 

  

	 	6.1.	As consideration for the grant of the rights and licenses hereunder, EVOTEC shall pay to ROCHE a down payment in the amount of 6 Million US Dollars (US$6 Mio) payable before
December 31, 2005 (“First Payment”). In addition, EVOTEC shall pay to ROCHE a second down payment in the amount of 2 Million US Dollars (US$2 Mio) payable before December 1, 2006 (“Second Payment”).

  

	7.	Payments to ROCHE. 

  

	 	7.1.	EVOTEC shall pay to ROCHE for a Compound developed for **** the following amounts as success fees in accordance with and at the times set out as follows: 

Milestones for **** 
  

					
	 Milestones 
	  	(US$)	 
	 Phase III Initiation
	  	US$	*	***
	 NDA Filing of first indication in US
	  	US$	*	***
	 NDA Filing of first indication in EU
	  	US$	*	***
	 NDA Filing of first indication in Japan
	  	US$	*	***
	 First Commercial Sale in US
	  	US$	*	***
	 First Commercial Sale in EU
	  	US$	*	***
	 First Commercial Sale in Japan
	  	US$	*	***
	 First time annual Net Sales exceed US$ ****
	  	US$	*	***
	 First time annual Net Sales exceed US$ ****
	  	US$	*	***
	 First time annual Net Sales exceed US$ ****
	  	US$	*	***

  

	 	7.2.	EVOTEC shall pay to ROCHE for a Compound developed only for an Other Indication the following amounts as success fees in accordance with and at the times set out as follows:

  
  
 * Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 13 

 Milestones for Other Indications 
  

					
	 Milestones
	  	(US$)	 
	 Phase II Initiation
	  	US$	*	***
	 Phase III Initiation
	  	US$	*	***
	 NDA Filing of first indication in US
	  	US$	*	***
	 NDA Filing of first indication in EU
	  	US$	*	***
	 NDA Filing of first indication in Japan
	  	US$	*	***
	 First Commercial Sale in US
	  	US$	*	***
	 First Commercial Sale in EU
	  	US$	*	***
	 First Commercial Sale in Japan
	  	US$	*	***
	 First time annual Net Sales exceed US$ ****
	  	US$	*	***
	 First time annual Net Sales exceed US$ ****
	  	US$	*	***
	 First time annual Net Sales exceed US$ ****
	  	US$	*	***

  

	 	7.3.	All milestone payments under Section 7.1 and 7.2. shall be payable within thirty (30) days as from achievement of the respective milestone by EVOTEC but only once with regard to a
Compound irrespective of how many times such milestone is achieved. If development of a Compound for an Other Indication is ceased and the Compound is then developed for ****, Section 7.1. shall apply for the applicable milestones.

 If the first Compound developed for **** is ceased, and the second Compound is then developed for ****, the Phase II
Initiation and the Phase III Initiation milestone payments shall not be payable, should the milestone (s) in question have already been paid for the first Compound. 
  

	 	7.4.	Equity. As Phase II Initiation milestone for ****, Roche shall be granted a certain amount of shares of Evotec at Phase II Initiation equaling an amount of EUR **** (the
“Shares”) at the following terms: 

 The Shares to be granted to Roche shall be calculated by dividing EUR ****
through **** of the average of the closing share price of Evotec shares at the German stock exchange on each of the twenty (20) trading days prior to above mentioned Phase II Initiation. 
 The Shares shall be delivered to Roche, free and clear of any liens and freely 
  
  
 * Portions of this
document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 14 

 tradable, at the latest two (2) months after the date of such Phase II Initiation. Evotec shall however
have the right to pay EUR **** in cash, including **** interest as of the Phase II Initiation, in case Evotec cannot issue the shares for any valid reason. 
  

	 	7.5.	Royalties. 

  

	 	7.5.1.	During the Royalty Term, EVOTEC shall pay to ROCHE royalties on Net Sales of a Product developed and registered for **** calculated separately in respect of each band of income in
each calendar year at the rate of royalty set out opposite the relevant band in the table below: 

  

				
	 Royalties
	  		
	 Royalties on Net Sales below US$ ****
	  	*	***
	 Royalties on Net Sales US$ ****-US$ ****
	  	*	***
	 Royalties on Net Sales above US$ ****
	  	*	***

  

	 	7.5.2.	During the Royalty Term, EVOTEC shall pay to ROCHE royalties on Net Sales of a Product developed and registered for an Other Indication in the amount of ****%, if Evotec has not
Sublicensed the Product in question. If Evotec has Sublicensed the Product in question, Roche shall receive ****% of the royalty rate received by Evotec from the Sublicensee but in any case not less than ****% of Net Sales of a Product; i.e. if
Evotec has agreed a royalty rate of ****% with the Sublicensee, Roche shall receive ****% of Net Sales. 

  

	 	7.6	Royalties Due Once. The obligation to pay royalties to ROCHE under this Agreement is imposed only once with respect to the same unit of Product. Sales of Product among
EVOTEC, its Affiliates and sub-licensees shall not be subject to a royalty, but shall become subject to a royalty only when sold to a Third Party. 

  

	 	7.7	The payments to be made under this Section 7 shall not include VAT, if any be due and payable thereon. 

  

	8.	Accounting Period and Royalty Reporting 

  

	 	8.1.	Accounting Period and Net Sales Accounting. An Accounting Period commencing semiannually respectively on January 1 and July 1, each being the first day of an

  
  
 * Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 15 

	 	 
Accounting Period, and finishing respectively on June 30 and December 31, each being the last day of an Accounting Period. Royalties on Net Sales
shall be paid in US$. Royalties on Net Sales shall be calculated semiannually as of June 30 and December 31 and shall be paid within the ninety (90) days after the end of each Accounting Period in which such Net Sales are done. With
respect to royalties due on Net Sales in the United States, the parties may elect to report and have paid such royalties directly from one of its Affiliates in the United States. Whenever for the purpose of calculating royalties conversion from any
foreign currency shall be required, such conversion shall be made as follows: 

 With regard to EVOTEC, when calculating
the Adjusted Gross Sales, the amount of such sales in foreign currencies shall at first be converted in accordance with then current standard practices in the respective company. 
  

	 	8.2.	Blocked Countries. If by reason of law a Party (“Paying Party”) is unable to convert to U.S. Dollars a portion of the amount due by it under this Agreement, then
such Party shall notify the other Party in writing and the other Party shall have the right to receive such portion. Upon written request from the other Party, the Paying Party shall pay to the other Party such portion, in the currency of any other
country designated by the other Party and legally available to the Paying Party. 

  

	 	8.3.	Royalty Reports. Each royalty payment shall be accompanied by a report summarizing for each Product the total Adjusted Gross Sales and Net Sales achieved during the relevant
six-month period, the currency conversion rates, if applicable, which royalty calculation is being applied, the total royalty payments due and the taxes withheld in accordance with Section 9.4. below, if any. 

  

	 	8.4.	Withholding Taxes. If provision is made in law or regulation of any country for withholding of taxes of any type, levies or other charges with respect to any royalty payable
under this Agreement, the party required to do so shall promptly pay such tax, levy or charge for and on behalf of the other party to the proper governmental authority. The paying party shall be entitled to deduct any such tax, levy or charge
actually paid from royalty due or, if no further payments are due, be promptly reimbursed by the other party, provided however that each party agrees to assist the other party, as may reasonably be necessary, in claiming exemption from such
deductions or withholdings under double taxation or similar agreement or treaty from time to time in force and in minimizing the amount required to be so withheld or 

  
  
 * Portions of this
document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 16 

	 	 
deducted, and provided further that the paying party shall provide such additional documentation from time to time as is needed for the other party to
confirm the payment of tax. 

  

	 	8.5.	Audit and Inspection. Either party and its Affiliates and Sublicensees shall keep, full, true and accurate books of account containing all particulars that may be necessary
for the purpose of verifying Net Sales and Adjusted Gross Sales and calculating all royalties payable to the other party. Such books of accounts shall be kept at their principal place of business. Each party or its authorized independent
public accountant has the right to engage, at its own expense, an independent public accountant of international reputation to perform, on behalf of the requesting party or its independent public accountant, an audit, conducted in accordance with
international accounting and auditing standards (IAAS), of such books and records of the other party and its Affiliates and Sublicensees that are deemed necessary by the other party to report on Net Sales of Product for the period or periods
requested by the requesting party and the correctness of any report or payments made under this Agreement. Upon timely request and at least thirty (30) days’ prior written notice from the requesting party, such audit shall be conducted as
an additional audit work during the other party’s annual audit of the countries specifically requested by the requesting party, during regular business hours in such a manner as to not unnecessarily interfere with the other party’s normal
business activities, and shall be limited to results in the two (2) full calendar years prior to audit notification. Such audit shall not be performed more frequently than once per calendar year nor more frequently than once with respect to
records covering any specific period of time. All information, data, documents and abstracts herein referred to shall be used only for the purpose of verifying royalty statements or compliance with this Agreement shall be treated as EVOTEC and ROCHE
Confidential Information. Audit results shall be shared by and be binding upon the parties. If the audit reveals an overpayment, one party shall promptly reimburse the other party for the amount of the overpayment. If the audit reveals an
underpayment, the parties shall promptly make up such underpayment. If the audit reveals that the royalties owed by one party for the countries specifically requested and for any calendar year in total have been understated by more than 10% (ten),
the other party shall, in addition, pay the reasonable costs of such additional audit work. The failure of one party to request verification of any royalty calculation within the period during which corresponding records must be maintained will be
deemed to be acceptance of the royalty reporting. 

  
  
 * Portions of this document marked with **** have been
omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 17 

	9.	Intellectual Property 

  

	 	9.1.	Inventions. ROCHE and EVOTEC recognize that during the Term of this Agreement inventions relating to the making, using or selling of Compound and/or Product may be generated
and result in patents. Therefore, the parties agree as follows: 

  

	 	9.1.1.	As to the inventions made solely by person(s) under the control of EVOTEC in the Field, EVOTEC shall have all of the rights it is entitled to receive from such employee(s) or
person(s) and shall become automatically EVOTEC Patent Rights,; 

  

	 	9.1.2.	As to any inventions made solely by person(s) under control of ROCHE in the Field, ROCHE shall have all of the rights they are entitled to receive from such person(s) and shall
become automatically ROCHE Patent Rights; 

  

	 	9.1.3.	Any inventions made jointly by persons under the control of both parties during the term of this Agreement in the Field shall be owned jointly by ROCHE and EVOTEC and shall become
automatically joint inventions. 

 Both parties represent that each of its or its Affiliates’ respective employees has
entered into a written contract of employment that provides for assignment of all inventions made by said employee during the course of his/her employment to the respective party taking into account the German Arbeitehmererfindungsgesetz.

  

	 	9.2.	Trademarks. EVOTEC shall select, own and maintain the trademark(s) for the marketed Products in the Territory. To the extent feasible, a single trademark shall be identified
and developed for use in connection with marketing of a given Product. 

  

	 	9.3.	Prosecution of Patent Rights.  

  

	 	9.3.1.	ROCHE shall have the sole responsibility for the prosecution and maintenance of the ROCHE Patent Rights. ROCHE has no obligation to file additional patents, unless EVOTEC explicitly
requests to file an additional patent within ROCHE Patent Rights and agrees to bear the cost and expenses therefore. Otherwise, the costs for the prosecution and the maintenance of the ROCHE Patent Rights shall be borne by ROCHE. ROCHE shall have
the right, but not the obligation, to defend and enforce the ROCHE Patent Rights. 

  
  
 * Portions of this document marked with **** have been
omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 18 

	 	9.3.2.	EVOTEC shall have the sole responsibility for the prosecution and maintenance of the EVOTEC Patent Rights. The costs for the prosecution and the maintenance of the EVOTEC Patent
Rights shall be borne by EVOTEC, subject to Section 9.4. below. 

 9.4. Assignment 
  

	 	9.4.1.	If ROCHE is no longer interested in prosecuting or maintaining any of the ROCHE Patent Rights, then ROCHE shall notify EVOTEC thereof. If EVOTEC asks for an assignment of any such
ROCHE Patent Rights, then ROCHE shall assign such ROCHE Patent Rights to EVOTEC free of any charge, provided that EVOTEC shall bear the costs for such assignments. 

  

	 	9.4.2.	If EVOTEC is no longer interested in prosecuting or maintaining any of the EVOTEC Patent Rights, then EVOTEC shall notify ROCHE thereof. If ROCHE asks for an assignment of any such
EVOTEC Patent Rights, then EVOTEC shall assign such EVOTEC Patent Rights to ROCHE free of any charge, provided that ROCHE shall bear the costs for such assignments. 

  

	 	9.5.	Defense and Enforcement. 

  

	 	9.5.1.	Infringement. Each party shall promptly provide written notice to the other party during the Term of this Agreement of any known infringement or suspected infringement by a
Third Party of any ROCHE Patent Rights or EVOTEC Patent Rights, and shall provide the other party with all evidence in its possession supporting such infringement or unauthorized use or misappropriation. 

  

	 	9.5.2.	Within a period of ninety (90) days after either party provides or receives such written notice with respect to its Patent Rights (“Decision Period”), the party which
Patent Rights are allegedly infringed, in its sole discretion, shall decide whether or not to initiate a suit or take other appropriate action and shall notify the other party in writing of its decision in writing (“Suit Notice”).

  
  
 * Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 19 

	 	9.5.3.	If the party which Patent Rights are allegedly infringed decides to bring a suit or take action and provides a respective Suit Notice, then such party may immediately commence such
suit or take such action. If the party which Patent Rights are allegedly infringed (i) does not in writing advise the other party within the Decision Period that it will commence suit or take action, or (ii) fails to commence suit or take
action within a reasonable time after providing Suit Notice, or (iii) abandons an action, then the other party shall thereafter have the right to commence suit or take action and shall provide written notice to the party which Patent Rights are
allegedly infringed of any such suit commenced or action taken by the other party. 

  

	 	9.5.4.	Upon written request, the party bringing suit or taking action (“Initiating Party”) shall keep the other party informed of the status of any such suit or action and shall
provide the other party with copies of all substantive documents and communications filed in such suit or action. The Initiating Party shall have the sole and exclusive right to select counsel for any such suit or action. 

 

	 	9.5.5.	The Initiating Party shall, except as provided below, pay all expenses of the suit or action, including, without limitation, the Initiating Party’s attorneys’ fees,
damages and court costs. Any damages, settlement fees or other consideration received as a result of such suit or action shall belong to the Initiating Party. 

  

	 	9.5.6.	If the Initiating Party believes it reasonably necessary, upon written request the other party shall join as a party to the suit or action but shall be under no obligation to
participate except to the extent that such participation is required as the result of its being a named party to the suit or action. At the Initiating Party’s written request, the other party shall offer reasonable assistance to the Initiating
Party in connection therewith at no charge to the Initiating Party except for reimbursement of reasonable out-of-pocket expenses incurred by the other party in rendering such assistance. The other party shall have the right to participate and be
represented in any such suit or action by its own counsel at its own expense. 

  

	 	9.5.7.	The Initiating Party shall not settle, agree to a consent judgment or otherwise voluntarily dispose of the suit or action without the written consent of the other party, which
consent shall not be unreasonably withheld. 

  
  
 * Portions of this document marked with **** have been
omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 20 

	10.	Confidential Information 

  

	 	10.1.	Non-Use and Non-Disclosure. During the Term of this Agreement and for five (5) years as from its termination for whatsoever reason, the receiving party shall
(i) treat Confidential Information provided by the disclosing party under this Agreement and all previous agreements as it would treat its own information of a similar nature, (ii) take all reasonable precautions not to disclose such
Confidential Information to Third Parties, without the disclosing party’s prior written consent, and (iii) not use such Confidential Information other than for fulfilling its obligations under this Agreement. 

  

	 	10.2.	Authorized Disclosure. Nothing in this Agreement shall prevent the Parties from disclosing Confidential Information to (i) Registration Authorities or other governmental
agencies of any country in the Territory to the extent required or desirable to secure government approval for the development, manufacture or sale of Product in the Territory in the Field, (ii) Third Party’s acting on behalf of one Party,
to the extent reasonably necessary for the development, manufacture or sale of Product in the Territory, or (iii) Third Parties to the extent reasonably necessary to market Product in the Territory, always to the extent necessary for such Party
to enjoy all its right under this Agreement. 

  

	11.	Term and Termination 

  

	 	11.1.	Term. This Agreement comes into effect on the Effective Date and will remain in force, unless earlier terminated, on a country-by-country and Product-by-Product basis until
expiry of the Royalty Term, whichever is later. Thereafter, the licenses granted hereunder shall be fully paid up and royalty-free. 

  

	 	11.2.	Termination.  

  

	 	11.2.1.	Termination by EVOTEC.  

  

	 	11.2.1.1.	Termination by EVOTEC during the period before the Second Payment. After EVOTEC has made its First Payment, EVOTEC shall have the right to terminate this Agreement in its
entirety with immediate effect giving written notice during the period from the Effective date to December 1, 2006. 

  
  
 * Portions of this document marked with **** have been
omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 21 

	 	11.2.1.2.	Termination by EVOTEC after the Second Payment. EVOTEC shall have the right to terminate this Agreement in its entirety or on a country-by-country or Product-by-Product basis
at any time with six (6) months prior written notice, provided ROCHE has not exercised its Development Option or Commercialisation Option. 

  

	 	11.2.2.	Termination for Breach. A Party (“non-breaching Party”) shall have the right to terminate this Agreement in its entirety or on a country-by-country or
Product-by-Product basis in the event the other Party (“breaching Party”) is in breach of any of its material obligations under this Agreement. The non-breaching Party shall provide written notice to the breaching party, which notice shall
identify the breach and the Products and countries in which the non-breaching party intends to have this Agreement terminate. The breaching Party shall have a period of one hundred and twenty (120) days after such written notice is provided to
cure such breach. If such breach is not cured within the one hundred and twenty day (120) period, this Agreement shall effectively terminate in such countries. The waiver by either Party of any breach of any term or condition of this Agreement
shall not be deemed a waiver as to any subsequent or similar breach. The waiver by either Party of any breach of any term or condition of this Agreement shall not be deemed a waiver as to any subsequent or similar breach. The right to terminate this
Agreement under this Section 12.2.3 is in addition to any other right and protection that may otherwise be available as a result of a breach, including, without limitation, the right to damages. 

  

	 	11.2.3.	Bankruptcy. Either Party may terminate this Agreement at any time with immediate effect by written notice to the other Party if the other Party is declared bankrupt or
insolvent, or if a receiver is appointed, or any procedures are commenced, voluntarily or involuntarily, by or against a Party under any bankruptcy or similar law, or in the near future it is reasonably anticipated that the Party is to be dissolved,
liquidated or bankrupt. 

  

	12.	Consequences of Termination 

  

	 	12.1.	Rights and Licenses. Upon termination of this Agreement, 

  

	 	12.1.1.	EVOTEC shall make its personnel and or other resources reasonably available to ROCHE as necessary to effect an orderly transition of development and commercial responsibilities,
with the reasonable cost of such personnel and resources to be born by EVOTEC for such services; 

  
  
 * Portions of this document marked with **** have been
omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 22 

	 	12.1.2.	all rights and licenses granted by ROCHE to EVOTEC under this Agreement (or, as applicable, in the country or with respect to that Product) shall terminate on the effective date of
termination. In the event of any such termination, the following shall apply and no compensation nor refund shall be due by either Party to the other Party, otherwise than damages as determined by a court of competent jurisdiction:

  

	 	12.1.3.	EVOTEC shall, upon ROCHE’s written request, smoothly and promptly assign and transfer to ROCHE, at no expense to ROCHE, in connection with the Territory or the terminated
countries (as applicable), all of EVOTEC’s right, title and interest in and to (i) all trademarks used for Product, (ii) all regulatory filings (such as INDs and drug master files), regulatory approvals, clinical trial agreements (to
the extent assignable and not cancelled), (iii) all data, results, clinical trials data, support documentation having arisen out of the development, materials and other information, in EVOTEC’s possession and control related to Product in
the Territory, and related to EVOTEC’s Patent Rights and Roche Know-How, (iv) all customer lists, marketing and promotional material, and all other documentation related to marketing, sale, and promotion of the Products in the Territory or
in the terminated country (as applicable), and (iv) during the termination notice period provide a reasonable number of person days of qualified personnel to transfer EVOTEC’s manufacturing technology to ROCHE. With respect to the
trademarks, the responsibility of preparing and filing of the documents for the recordal of the assignments with the competent authorities in each applicable country and any action required ancillary, shall be born by ROCHE. However, each party
shall bear its expenses caused by its activities in connection with the assignments and transfer of the trademarks. 

  

	 	12.1.4.	EVOTEC shall further make Commercially Reasonable Efforts to continue making the Product provided however that, EVOTEC shall transfer at its own expenses to ROCHE all technical and
industrial know how related to the manufacturing of the Product for use by ROCHE and shall provide reasonable assistance and support (up to a reasonable number of person/days of qualified personnel) as may be reasonably required by ROCHE to be in a
position to make the Product itself. 

  
  
 * Portions of this document marked with **** have been
omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 23 

	 	12.1.5.	ROCHE shall have the right to disclose such filings, approvals and data to (i) governmental agencies of the country to the extent required or desirable to secure government
approval for the development, manufacturing or sale of Product in the country, (ii) Third Parties acting on behalf of ROCHE, its Affiliates or Sublicensees, to the extent reasonably necessary for the development, manufacture, or sale of Product
in the country, and (iii) Third Parties to the extent reasonably necessary to market Product in the country. 

  

	 	12.1.6.	For a given Product and country so terminated, or for the Territory in the case of termination of this Agreement in its entirety, EVOTEC shall grant to ROCHE an exclusive (even as
to EVOTEC), sub-licensable, royalty-free license under all elements of EVOTEC Patents and Know-how that are not severable from the Product, and a non-exclusive, sub-licensable, royalty-free license under all other EVOTEC Patents and Know-how to
make, have made, use, offer for sale, sell and import such Product in such country or the Territory, as applicable. 

  

	 	12.1.7.	EVOTEC shall agree to take such actions and execute such instruments, agreements and documents as are necessary to affect the foregoing. 

  

	 	12.2.	Royalty and Payment Obligations. Expiration of this Agreement pursuant to Section 12.1. above, and termination of this Agreement will release both parties from any
obligation to pay royalties or make any payments to the other party which would otherwise become due or payable on or after the effective date of termination. 

  

	13.	Indemnification 

  

	 	13.1.	Indemnification by ROCHE. ROCHE shall indemnify, hold harmless and defend EVOTEC and its directors, officers, employees and agents from and against any and all losses,
expenses, cost of defense (including without limitation attorneys’ fees, witness fees, damages, judgments, fines and amounts paid in settlement) and any amounts EVOTEC becomes legally obligated to pay because of any claim or claims against it
to the extent that such claim or claims arise out of activities related to Product in the Field (e.g. product liability claims) conducted by or on behalf of ROCHE, except to the extent such losses, expenses, costs and amounts are due to the
negligence or misconduct or failure to act of EVOTEC. 

  

	 	13.2.	Indemnification by EVOTEC. EVOTEC shall indemnify, hold harmless and defend ROCHE and its directors, officers, employees and agents from and against any and

  
  
 * Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 24 

	 	 
all losses, expenses, cost of defense (including without limitation attorneys’ fees, witness fees, damages, judgments, fines and amounts paid in
settlement) and any amounts ROCHE becomes legally obligated to pay because of any claim or claims against it to the extent that such claim or claims arise out of activities related to Product in the Field (e.g. product liability claims) conducted by
or on behalf of EVOTEC, except to the extent such losses, expenses, costs and amounts are due to the negligence or misconduct or failure to act of ROCHE. 

  

	 	13.3.	Procedure. In the event of a claim by a third party against a party entitled to indemnification under this Agreement (“Indemnified Party”), the Indemnified Party
shall promptly notify the other party (“Indemnifying Party”) in writing of the claim and the Indemnifying Party shall undertake and solely manage and control, at its sole expense, the defense of the claim and its settlement. The
Indemnified Party shall cooperate with the Indemnifying Party and may, at its option and expense, be represented in any such action or proceeding by counsel of its choice. The Indemnifying Party shall not be liable for any litigation costs or
expenses incurred by the Indemnified Party without the Indemnifying Party’s written consent. The Indemnifying Party shall not settle any such claim unless such settlement fully and unconditionally releases the Indemnified Party from all
liability relating thereto, unless the Indemnified Party otherwise agrees in writing. 

  

	14.	Representations and Warranties 

  

	 	14.1.	Mutual Representations and Warranties. Each party hereby represents and warrants: 

  

	 	14.1.1.	Authority. Such party has the full right and authority to enter into this Agreement, and that it is not aware of any impediment that would inhibit its ability to perform its
obligations under this Agreement. 

  

	 	14.1.2.	Material Facts. Such party has disclosed all information in its possession or control which is material to the other party entering into this Agreement, and such information
does not contain any untrue statement of material fact or omit to state a material fact. 

  

	 	14.2.	Roche Representation on License Grant. ROCHE has the right to grant EVOTEC the rights and licenses described in this Agreement. 

  
  
 * Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 25 

	 	14.3.	Further Roche Representations and Warranties. ROCHE represents and warrants that, as of the Effective Date, 

 (i) it has no knowledge of any claims by any Third Party that the use of the Compounds licensed under the terms and conditions of this Agreement
infringes any proprietary rights of any Third Party, 
 (ii) to the best of its knowledge, there are no legal actions, suits or other
proceedings relating to the Compounds licensed under the terms and conditions of this Agreement. 
  

	 	14.4.	As of the Effective Date, to the best of Roche’s knowledge, (i) ROCHE does not have a compound being developed as MAO-B inhibitor at the stage of Clinical Candidate
Selected (as defined by Roche’s internal policies) or at a later stage and (ii) ROCHE does not intend to develop a compound as MAO-B inhibitor. The term “Roche” used in this Section 14.4. does not include Chugai and/or
Genentech. 

  

	 	14.5.	Until the earlier of (i) a period of three (3) years after the Effective Date and (ii) End of Phase IIb, ROCHE will not grant to a Third Party a license to a compound
that is a) falling under the ROCHE Patent Rights or related patent rights specified in Appendix 4 (“Related Patent Rights”) and b) developed by ROCHE as MAO-B inhibitor. The term “Roche” used in this Section 14.5. does not
include Chugai and/or Genentech. 

  

	15.	Governing Law and Dispute Resolutions 

  

	 	15.1.	Governing Law. This Agreement shall be governed by and construed in accordance with the laws of Switzerland, without reference to its conflict of laws principles, and shall
not be governed by the United Nations Convention of International Contracts on the Sale of Goods (the Vienna Convention). 

  

	 	15.2.	Disputes. Unless otherwise set forth in this Agreement, in the event of a dispute arising out of or under this Agreement between the parties, such dispute shall be referred
to the respective executive officers of the parties designated below or their designees, for good faith negotiations attempting to resolve the dispute. The designated executive officers are as follows: 

  
  
 * Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 26 

			
	 For EVOTEC:
	 	CEO
		
	 For ROCHE:
	 	Head of Pharma Partnering

  

	 	15.3.	Arbitration. In the event of any controversy or claim arising out of or relating to any provision of this Agreement or the breach thereof, the parties shall try to settle
those conflicts amicably between themselves as set forth in Section 16.2. Should they fail to agree within two (2) months after such dispute has first arisen, any controversy, dispute or claim which may arise out of or in connection with
this Agreement, or the breach, termination or validity thereof, shall be finally settled by arbitration in accordance with the Rules of Conciliation and Arbitration of the International Chamber of Commerce, under preclusion of the otherwise ordinary
recourse to the courts. The arbitral tribunal can also decide about the effectiveness of this arbitration clause. The arbitral tribunal shall consist of three arbitrators. The place of arbitration shall be Zürich, Switzerland. The language to
be used shall be English. 

  

	16.	Publicity 

  

	 	16.1.	Release of Information. Neither party shall release any information (e.g. press release) related to this Agreement, including its terms, without the prior written consent of
the other party, unless release of such information is required by law or regulated authorities. If a party (“Releasing Party”) determines that it is required by law to release information relating to this Agreement to a Third Party, it
shall so notify the other party prior to the release of such information, including the text of the information proposed for release, in sufficient time for the other party to comment. The other party shall have the right to comment regarding the
necessity of such disclosure and the text proposed for disclosure, which comment the Releasing Party must consider and include unless prohibited by law. 

  

	 	16.2.	Disclosure of Information to EVOTEC investors. EVOTEC shall have the right to release any information related to this Agreement, including its terms, to potential investors,
provided that each such investor has previously entered into a written confidentiality agreement at least substantially similar to the confidentiality obligations under Section 11.1. 

  

	 	16.3.	Scientific Publications. Notwithstanding Section 16.1, EVOTEC shall have the right to publish at any time any results relating to the research and development activities
hereunder with respect to Compounds or Products in the Field, provided however that ROCHE receives a copy thereof. ROCHE shall have the right to publish at any time 

  
  
 * Portions of this
document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 27 

	 	 
any results relating to the research and development activities hereunder with respect to Compounds or Products in the Field. Evotec shall be permitted to
publish any data on its clinical data registry according to its internal guidelines, provided however that ROCHE has the right to approve any data of EVOTEC prior to publication. 

  

	17.	Miscellaneous 

  

	 	17.1.	Survival. Sections 10, 13, 15, 17. shall survive the expiration or termination of this Agreement for any reason. 

  

	 	17.2.	Agency. Neither party is, nor will be deemed to be, an employee, agent or representative of the other party for any purpose. Each party is an independent contractor, not an
employee or partner of the other party. Neither party shall have the authority to speak for, represent or obligate the other party in any way without prior written authority from the other party. 

  

	 	17.3.	Amendment. No amendment or modification hereof shall be valid or binding upon the parties unless made in writing and signed by both parties. 

  

	 	17.4.	Assignment. This Agreement shall not be assignable in part or in whole by any party without the prior written consent of the other; provided, however, that either party,
without notice and at any time for any reason, may assign this Agreement in whole or in part to (i) any of its Affiliates who agree to be bound by the terms and conditions of this Agreement or (ii) any successor of such party by merger or
sale of all or substantially all of its business assets to which this Agreement relates. In the event of any such permitted assignment, the party making the assignment will remain jointly and severally liable and responsible for the performance and
observance of all its duties and obligations hereunder. 

  

	 	17.5.	Notices. Any notice or other communication to be given under this Agreement, unless otherwise specified, shall be in writing and shall be deemed to have been provided when
delivered to the addressee at the address listed below (i) on the date of delivery if delivered in person or (ii) one (1) day after mailing to the other party by express mail or overnight delivery service, which obtains a signed
receipt, or (iii) three (3) days after mailing by registered or certified mail, postage paid: 

  
  
 * Portions of this document marked with **** have been
omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 28 

 In the case of ROCHE: 
 F. Hoffmann-La Roche Ltd 
 attn. Legal Department 
 Grenzacherstrasse 124 
 4070 Basel

 Switzerland 
 With a copy
to: Hoffmann-La Roche Inc. 
 attn: Corporate Secretary 
 340 Kingsland Street 
 Nutley, New Jersey 07110 
 USA 
 In the case of EVOTEC 
 Evotec AG 
 Attn. CEO 
 Schnackenburgallee 114 
 22525 Hamburg

 Germany 
 Either party may
change its address for communications by a notice in writing to the other party in accordance with this Section. 
  

	 	17.6.	Force Majeure. Any prevention, delay or interruption of performance (collectively “Delay”) by any party under this Agreement shall not be considered a breach of
this Agreement if and to the extent caused by occurrences beyond the reasonable control of the party affected by the force majeure, including but not limited to acts of God, embargoes, governmental restrictions, general strike, fire, flood,
earthquake, explosion, riots, wars, civil disorder, rebellion or sabotage. The affected party shall immediately notify the other party upon the commencement and end of the Delay and any time for performance hereunder by both parties shall be
extended by the actual time of Delay. If the Delay resulting from the force majeure exceeds six (6) months, the other party, upon written notice to the affected party, may elect to (i) treat such Delay as a material breach, or
(ii) extend the term of this Agreement for an amount of time equal to the Delay. 

  

	 	17.7.	Severability. If any term or condition of this Agreement is held by a court of competent jurisdiction to be unenforceable for any reason, it shall, if possible, be
interpreted to achieve the intent of the parties to this Agreement rather than voided. If not capable of such interpretation, the parties shall in good faith seek to agree on an alternative provision reflecting the intent of the parties which is
enforceable. In any event, all other terms, conditions and provision of this Agreement shall be deemed valid and enforceable to the full extent. 

  

 
 * Portions of this document marked with **** have
been omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 29 

 IN WITNESS WHEREOF, the parties hereto have caused their authorized representatives to execute this
Agreement by signing below. 
 

 
 List of Appendices: 
 Compound/Roche Patent Rights: Appendix 1 
 Roche Know-How: Appendix 2 
 Development Plan: Appendix 3 
 Related Patent Rights: Appendix 4 
  
  
 * Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 30 

 AMENDMENT NO 1 
 to the 
 LICENSE AGREEMENT 
 between 
 F. Hoffmann-L Roche Ltd 
 with an office and place of business at Grenzacherstr.124, CH-4070 Basel, Switzerland (“ROCHE Basel”) 
 and

 Hoffmann-La Roche Inc. 
 with an office and place of business
at 340 Kingsland Street, Nutley, NJ 07110, USA (“ROCHE Nutley”; ROCHE Basel and ROCHE Nutley together referred to as “ROCHE”) 
 on the
one hand 
 and 
 Evotec Neurosciences GmbH, Schnackenburgallee
114, 22525 Hamburg, Germany (“EVOTEC”) 
 on the other hand 
 effective as of January 6, 2006. 
  
  
 WHEREAS, EVOTEC and ROCHE have signed the above mentioned License Agreement (“Agreement”); 
 WHEREAS, during the year of 2006 some changes of the License Agreement have become necessary and desirable for both parties; 
 NOW, THEREFORE, the Agreement shall be amended as follows: 
  
  
 * Portions of this document marked with **** have been
omitted pursuant to a request for confidential treatment submitted with the SEC. 

	1.	Definitions 

 The definition 1.2. of the Agreement
“Commercialisation Option” shall be deleted. 
 The definition 1.10. of the Agreement “End of Phase III” shall be deleted. 
 The definition 1.15. of the Agreement “Development Option” shall be deleted. 
 Section 1.19. of the Agreement shall be amended and read as follows: 
 “1.19. Other
Indications” shall mean all indications other than ****.” 
  

	2.	Grant of Rights 

 Section 2.2. of the Agreement shall be
amended and read as follows: 
 “2.2. Right to Sublicense. EVOTEC shall have the right to sublicense its rights under
Section 2.1. If Evotec grants such as sublicense, Evotec shall ensure that all of the applicable terms and conditions of this Agreement shall apply to the Affiliate or Third Party Sublicensee to the same extent as they apply to Evotec for all
purposes. Evotec assumes full responsibility for the performance of all obligations so imposed on such Affiliate or Third Party Sublicensee and will itself account to Roche for all payments due under this Agreement by reason of such
sublicense.” 
  

	4.	Option rights of ROCHE 

 Section 4. of the Agreement
shall be deleted. 
  

	5.	Diligence 

 Section 5.1.1. of the Agreement shall be
amended and read as follows: 
 “5.1.1. At all times during the term of this Agreement, EVOTEC will use and will cause its affiliates and
Sublicensees to use Commercially Reasonable Efforts to proceed with the development, manufacture, marketing, distribution and sale of at least one Compound and/or Product.” 
  
  
 * Portions of this
document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 -2- 

	6.	Down payments 

 Section 6.1. of the Agreement shall be
amended and read as follows: 
 “6.1. As consideration for the rights and licenses hereunder, EVOTEC shall pay to ROCHE a down payment in
the amount of 6 Million US Dollars (US$6 Mio) payable before December 31, 2005 (“First Payment”). In addition, EVOTEC shall pay to ROCHE a second down payment in the amount of 2 Million US Dollars (US$2 Mio) payable before
April 30, 2007 (“Second Payment”).” 
  

	7.	Payments to ROCHE 

 Section 7.1. of the Agreement shall
be amended and read as follows: 
 “7.1. EVOTEC shall pay to ROCHE for a Compound developed for **** the following amounts as success
fees in accordance with and at the times set out as follows: 
 Milestones for **** 
  

			
	 Milestones
	  	(US$)
	 Phase III Initiation
	  	****
	 NDA Filing of first indication in US
	  	****
	 NDA Filing of first indication in EU
	  	****
	 NDA Filing of first indication in Japan
	  	****
	 First Commercial Sales in US
	  	****
	 First Commercial Sales in EU
	  	****
	 First Commercial Sales in Japan
	  	****
	 First time annual Net Sales exceed US$****
	  	****
	 First time annual Net Sales exceed US$****
	  	****
	 First time annual Net Sales exceed US$****
	  	
 ****

  
  
 * Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 -3- 

 Section 7.3. and 7.4. of the Agreement shall be amended and read as follows: 
 “7.3. All milestone payments under Section 7.1. and 7.2. shall be payable within thirty (30) days as from achievement of the respective
milestone by EVOTEC but only once with regard to a Compound irrespective if how many times such milestone is achieved. If development of a Compound for an Other Indication is ceased and the Compound is then developed for ****, Section 7.1.
shall apply for the applicable milestones from then onwards. 
 “7.4. Equity. As Phase II Initiation milestone for ****, Roche
shall be granted a certain amount of shares of Evotec at Phase II Initiation equaling an amount of EUR 2,700,000 (two million seven hundred thousand Euros) (the “Shares”) at the following terms: 
 The Shares to be granted to Roche shall be calculated by dividing EUR 2,700,000 (two million seven hundred thousand Euros) through 90% (ninety per cent.)
of the average of the closing share price of Evotec shares at the German stock exchange on each of the twenty (20) trading days prior to above mentioned Phase II Initiation. The Shares shall be delivered to Roche free and clear of any liens and
freely tradable at the latest two (2) months after the date of such Phase II Initiation Evotec shall however have the right to pay EUR 2,700,000 (two million seven hundred thousand Euros) in cash, including 5% (five per cent.) interest as of
the Phase II Initiation, in case Evotec cannot issue the shares for any valid reason.” 
 Section 7.5.1. of the Agreement shall be amended and read
as follows: 
 “7.5.1. During the Royalty Term, EVOTEC shall pay to ROCHE royalties on Net Sales of a Product developed and registered
for **** in the amount of ****.” 
  
  
 * Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 -4- 

	11.	Termination 

 Section 11.2.1.1. of the Agreement shall
be deleted. 
 Section 11.2.1.2. of the Agreement shall be renamed 11.2.1. and amended and read as follows: 
 “11.2.1. Termination by EVOTEC after the Second Payment. EVOTEC shall have the right to terminate this Agreement in its entirety or on a
country-by-country or Product-by-Product basis at any time with six (6) months prior written notice.” 
 All other stipulations of the Agreement
shall remain in place unchanged. 
 IN WITNESS WHEREOF, the parties hereto have caused their authorized representatives to execute this Agreement by signing
below. 
 

 
  
  
 * Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 -5- 

 Compound/Roche Patent Rights: Appendix 1 (MAOB – ****) 
  

																			
	 Country
 Code
	  	 Country
	  	Filing Date	  	Application No.	  	Publication No.	  	Patent
No.	  	Grant
Date	  	Expiry
Date	  	 Status
	  	 Holder

	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  	****	  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  		  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  	****	  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  		  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  		  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  		  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  	/	  	/	  	/	  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  	****	  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  		  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  	****	  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  		  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  		  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  		  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	 ****
	  	Roche Basel

  
 * Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 

																			
	****	  	****	  	****	  	****	  		  		  		  	****	  	****	  	Roche Basel
	****	  	****	  	****	  	****	  		  		  		  	****	  	****	  	Roche Basel
	****	  	****	  	****	  	****	  		  		  		  		  	****	  	Roche Basel
	****	  	****	  	****	  	****	  		  		  		  		  	****	  	Roche Basel
	****	  	****	  	****	  	****	  		  		  		  	****	  	****	  	Roche Basel
	****	  	****	  	****	  	****	  		  		  		  	****	  	****	  	Roche Basel
	****	  	****	  	****	  	****	  		  		  		  		  	****	  	Roche Basel
	****	  	****	  	****	  	****	  		  		  		  		  	****	  	Roche Basel
	****	  	****	  	****	  	****	  		  		  		  	****	  	****	  	Roche Basel
	****	  	****	  	****	  	****	  	****	  		  		  		  	****	  	Roche Basel
	****	  	****	  	****	  	****	  		  		  		  		  	****	  	Roche Basel
	****	  	****	  	****	  	****	  		  		  		  		  	****	  	Roche Basel
	****	  	****	  	****	  	****	  		  		  		  		  	****	  	Roche Basel
	****	  	****	  	****	  	****	  		  		  		  	****	  	****	  	Roche Basel
	****	  	****	  	****	  	****	  	****	  	****	  	****	  	****	  	****	  	Roche Nutley
	****	  	****	  	****	  	****	  	****	  		  		  		  	****	  	Roche Nutley
	****	  	****	  	****	  	****	  		  		  		  		  	****	  	Roche Basel
	****	  	****	  	****	  	****	  		  		  		  	****	  	****	  	Roche Basel
	****	  	****	  	****	  	****	  	****	  		  		  		  	****	  	Roche Basel

  
 * Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 

 Compound/Roche Patent Rights: Appendix 1 (MAOB – Case ****) 
  

																			
	 Country
Code
	  	 Country
	  	Filing Date	  	Application No.	  	Grant
Date	  	Publication No.	  	Patent
No.	  	Expiry
Date	  	 Status
	  	 Holder

	 ****
	  	 ****
	  	****	  	****	  		  	****	  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  		  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  		  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  	/	  	/	  	/	  	/	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  	****	  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  		  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  	****	  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  		  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  	****	  		  	****	  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  		  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  		  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  	****	  		  	****	  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  		  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  		  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	 ****
	  	Roche Basel

  
 * Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

																			
	****	  	****	  	****	  	****	  		  		  		  	****	  	****	  	Roche Basel
	****	  	****	  	****	  	****	  		  		  		  		  	****	  	Roche Basel
	****	  	****	  	****	  	****	  		  		  		  		  	****	  	Roche Basel
	****	  	****	  	****	  	****	  		  		  		  	****	  	****	  	Roche Basel
	****	  	****	  	****	  	****	  		  	****	  		  		  	****	  	Roche Basel
	****	  	****	  	****	  	****	  		  		  		  		  	****	  	Roche Basel
	****	  	****	  	****	  	****	  		  		  		  	****	  	****	  	Roche Basel
	****	  	****	  	****	  	****	  		  	****	  		  		  	****	  	Roche Nutley
	****	  	****	  	****	  	****	  		  		  		  		  	****	  	Roche Basel
	****	  	****	  	****	  	****	  		  	****	  		  		  	****	  	Roche Basel

  
 * Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 Roche Know-How: Appendix 2 
  

													
	 Hit
	  	Relevance	  	 Title
	  	 Author(s)
	  	Document Date	  	Pages	  	Report No
	1	  	69	  	****	  	****	  	18.05.2005	  	380	  	****
	2	  	67	  	****	  	****	  	18.05.2005	  	415	  	****
	3	  	63	  	****	  	****	  	24.01.2005	  	30	  	****
	4	  	49	  	****	  	****	  	29.04.2003	  	9	  	****
	5	  	49	  	****	  	****	  	27.11.2003	  	36	  	****
	6	  	48	  	****	  	****	  	27.11.2003	  	35	  	****
	7	  	48	  	****	  	****	  	28.04.2005	  	24	  	****
	8	  	47	  	****	  	****	  	14.03.2005	  	121	  	****
	9	  	47	  	****	  	****	  	30.07.2004	  	41	  	****

  
 * Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 Page 1 of 6 

													
	10	  	47	  	****	  	****	  	23.04.2003	  	10	  	****
	11	  	47	  	****	  	****	  	17.05.2005	  	335	  	****
	12	  	47	  	****	  	****	  	09.01.2004	  	29	  	****
	13	  	46	  	****	  	****	  	25.08.2004	  	35	  	****
	14	  	46	  	****	  	****	  	09.01.2004	  	37	  	****
	15	  	46	  	****	  	****	  	30.01.2004	  	15	  	****
	16	  	46	  	****	  	****	  	28.04.2005	  	23	  	****
	17	  	46	  	****	  	****	  	29.09.2004	  	72	  	****

  
 * Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 Page 2 of 6 

													
	18	  	46	  	****	  	****	  	10.12.2004	  	21	  	****
	19	  	46	  	****	  	****	  	09.08.2004	  	39	  	****
	20	  	45	  	****	  	****	  	10.05.2005	  	21	  	****
	21	  	45	  	****	  	****	  	20.04.2005	  	9	  	****
	22	  	45	  	****	  	****	  	22.02.2005	  	75	  	****
	23	  	45	  	****	  	****	  	06.09.2004	  	40	  	****
	24	  	45	  	****	  	****	  	16.05.2003	  	19	  	****
	25	  	45	  	****	  	****	  	26.10.2004	  	3	  	****
	26	  	45	  	****	  	****	  	15.06.2005	  	473	  	****

  
 * Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 Page 3 of 6 

													
	27	  	45	  	****	  	****	  	10.03.2005	  	220	  	****
	28	  	45	  	****	  	****	  	22.11.2004	  	85	  	****
	29	  	45	  	****	  	****	  	28.05.2005	  	11	  	****
	31	  	45	  	****	  	****	  	18.05.2005	  	15	  	****
	32	  	45	  	****	  	****	  	31.01.2003	  	15	  	****
	33	  	44	  	****	  	****	  	16.12.2003	  	158	  	****
	34	  	44	  	****	  	****	  	17.05.2005	  	12	  	****
	35	  	44	  	****	  	****	  	16.04.2004	  	2	  	****
	36	  	44	  	****	  	****	  	14.04.2005	  	79	  	****

  
 * Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 Page 4 of 6 

													
	37	  	44	  	****	  	****	  	24.01.2005	  	24	  	****
	38	  	44	  	****	  	****	  	22.02.2005	  	131	  	****
	39	  	44	  	****	  	****	  	27.11.2003	  	218	  	****
	40	  	44	  	****	  	****	  	30.04.2003	  	10	  	****
	41	  	44	  	****	  	****	  	24.02.2005	  	17	  	****
	42	  	44	  	****	  	****	  	26.07.2004	  	18	  	****
	43	  	43	  	****	  	****	  	09.08.2004	  	42	  	****
	44	  	43	  	****	  	****	  	29.06.2004	  	18	  	****
	46	  	43	  	****	  	****	  	02.10.2004	  	16	  	****

  
 * Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 Page 5 of 6 

													
	47	  	43	  	****	  	****	  	01.10.2004	  	17	  	****
	48	  	43	  	****	  	****	  	12.03.2004	  	35	  	****

  
 * Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 Page 6 of 6 

 Roche Know-How: Appendix 2 
  

													
	 Hit
	  	Relevance	  	 Title
	  	 Author(s)
	  	Document Date	  	Pages	  	Report No
	1	  	76	  	****	  	****	  	30.04.2005	  	534	  	****
	2	  	65	  	****	  	****	  	06.04.2004	  	12	  	****
	3	  	63	  	****	  	****	  	31.01.2005	  	309	  	****
	4	  	63	  	****	  	****	  	24.02.2005	  	25	  	****
	5	  	63	  	****	  	****	  	08.01.2004	  	42	  	****
	6	  	62	  	****	  	****	  	26.08.2003	  	39	  	****
	7	  	62	  	****	  	****	  	12.03.2003	  	38	  	****
	8	  	60	  	****	  	****	  	11.12.2003	  	461	  	****
	9	  	60	  	****	  	****	  	30.03.2004	  	475	  	****
	10	  	60	  	****	  	****	  	16.02.2005	  	43	  	****
	12	  	50	  	****	  	****	  	21.01.2003	  	8	  	****

  
 * Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 Page 1 of 11 

													
	13	  	50	  	****	  	****	  	12.11.2002	  	7	  	****
	14	  	50	  	****	  	****	  	21.01.2003	  	8	  	****
	15	  	49	  	****	  	****	  	07.04.2003	  	7	  	****
	16	  	49	  	****	  	****	  	11.04.2003	  	6	  	****
	17	  	48	  	****	  	****	  	22.02.2005	  	8	  	****
	18	  	48	  	****	  	****	  	14.05.2004	  	33	  	****
	19	  	48	  	****	  	****	  	08.01.2004	  	46	  	****
	20	  	48	  	****	  	****	  	22.07.2003	  	46	  	****
	21	  	48	  	****	  	****	  	12.11.2002	  	23	  	****
	22	  	48	  	****	  	****	  	28.02.2003	  	6	  	****

  
 * Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 Page 2 of 11 

													
	23	  	48	  	****	  	****	  	14.03.2003	  	8	  	****
	24	  	48	  	****	  	****	  	17.09.2002	  	6	  	****
	25	  	48	  	****	  	****	  	17.09.2002	  	7	  	****
	26	  	48	  	****	  	****	  	11.09.2002	  	7	  	****
	27	  	48	  	****	  	****	  	10.09.2002	  	6	  	****
	28	  	47	  	****	  	****	  	14.05.2004	  	33	  	****
	29	  	47	  	****	  	****	  	12.03.2004	  	35	  	****
	30	  	47	  	****	  	****	  	12.07.2004	  	31	  	****
	31	  	47	  	****	  	****	  	06.11.2003	  	30	  	****

  
 * Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 Page 3 of 11 

													
	32	  	47	  	****	  	****	  	25.04.2003	  	33	  	****
	33	  	47	  	****	  	****	  	14.05.2003	  	31	  	****
	34	  	47	  	****	  	****	  	12.05.2003	  	28	  	****
	35	  	47	  	****	  	****	  	23.05.2003	  	43	  	****
	36	  	47	  	****	  	****	  	27.05.2003	  	43	  	****
	37	  	47	  	****	  	****	  	19.01.2004	  	112	  	****
	38	  	46	  	****	  	****	  	28.04.2005	  	449	  	****

  
 * Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 Page 4 of 11 

													
	39	  	46	  	****	  	****	  	06.11.2003	  	31	  	****
	40	  	46	  	****	  	****	  	09.07.2004	  	30	  	****
	41	  	46	  	****	  	****	  	24.05.2004	  	180	  	****
	42	  	46	  	****	  	****	  	18.12.2003	  	22	  	****
	43	  	46	  	****	  	****	  	27.05.2003	  	27	  	****
	44	  	46	  	****	  	****	  	26.05.2003	  	26	  	****
	45	  	46	  	****	  	****	  	29.04.2005	  	228	  	****
	46	  	46	  	****	  	****	  	14.05.2004	  	16	  	****

  
 * Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 
  
  
  

 Page 5 of 11 

													
	47	  	46	  	****	  	****	  	23.05.2004	  	14	  	****
	48	  	46	  	****	  	****	  	07.05.2004	  	66	  	****
	49	  	46	  	****	  	****	  	11.05.2004	  	34	  	****
	50	  	46	  	****	  	****	  	11.08.2003	  	36	  	****
	51	  	45	  	****	  	****	  	15.02.2005	  	15	  	****
	52	  	45	  	****	  	****	  	01.10.2004	  	38	  	****
	53	  	45	  	****	  	****	  	31.07.2002	  	19	  	****
	54	  	45	  	****	  	****	  	10.02.2005	  	18	  	****
	55	  	45	  	****	  	****	  	03.06.2005	  	610	  	****

  
 * Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 Page 6 of 11 

													
	56	  	45	  	****	  	****	  	03.06.2005	  	183	  	****
	57	  	45	  	****	  	****	  	17.01.2005	  	115	  	****
	58	  	45	  	****	  	****	  	15.09.2004	  	46	  	****
	59	  	45	  	****	  	****	  	18.05.2004	  	15	  	****
	60	  	45	  	****	  	****	  	12.05.2004	  	18	  	****
	61	  	45	  	****	  	****	  	31.12.2003	  	234	  	****
	62	  	45	  	****	  	****	  	10.06.2005	  	21	  	****
	63	  	45	  	****	  	****	  	26.09.2003	  	32	  	****
	64	  	45	  	****	  	****	  	27.02.2004	  	28	  	****

  
 * Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 Page 7 of 11 

													
	65	  	45	  	****	  	****	  	06.06.2002	  	15	  	****
	66	  	44	  	****	  	****	  	15.07.2004	  	11	  	****
	67	  	44	  	****	  	****	  	18.02.2005	  	106	  	****
	68	  	44	  	****	  	****	  	30.01.2003	  	194	  	****
	70	  	44	  	****	  	****	  	19.06.2002	  	14	  	****
	71	  	44	  	****	  	****	  	02.03.2005	  	142	  	****
	72	  	44	  	****	  	****	  	16.09.2004	  	175	  	****
	73	  	44	  	****	  	****	  	18.12.2002	  	167	  	****
	74	  	44	  	****	  	****	  	03.10.2002	  	10	  	****

  
 * Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 Page 8 of 11 

													
	75	  	44	  	****	  	****	  	04.08.2004	  	139	  	****
	76	  	44	  	****	  	****	  	30.01.2003	  	229	  	****
	77	  	43	  	****	  	****	  	21.12.2004	  	22	  	****
	78	  	43	  	****	  	****	  	19.12.2003	  	21	  	****
	79	  	43	  	****	  	****	  	28.01.2003	  	29	  	****
	80	  	43	  	****	  	****	  	23.10.2003	  	4	  	****
	81	  	43	  	****	  	****	  	14.05.2004	  	7	  	****
	82	  	43	  	****	  	****	  	15.06.2005	  	473	  	****

  
 * Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 Page 9 of 11 

													
	83	  	43	  	****	  	****	  	20.04.2005	  	9	  	****
	84	  	43	  	****	  	****	  	29.01.2004	  	17	  	****
	85	  	43	  	****	  	****	  	28.01.2004	  	17	  	****
	86	  	43	  	****	  	****	  	16.01.2004	  	22	  	****
	90	  	43	  	****	  	****	  	06.05.2004	  	106	  	****
	93	  	43	  	****	  	****	  	26.11.2003	  	21	  	****
	97	  	43	  	****	  	****	  	16.06.2003	  	26	  	****
	98	  	43	  	****	  	****	  	02.07.2003	  	59	  	****

  
 * Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 Page 10 of 11 

													
	102	  	43	  	****	  	****	  	25.07.2005	  	26	  	****
	116	  	36	  	****	  	****	  	16.06.2003	  	25	  	****
	117	  	36	  	****	  	****	  	18.08.2003	  	39	  	****
	118	  	36	  	****	  	****	  	02.12.2003	  	16	  	****
	119	  		  	****	  		  		  		  	****
	120	  		  	****	  		  		  		  	****
	121	  		  	****	  		  		  		  	****
		  		  	****	  		  		  		  	****

  
 * Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 Page 11 of 11 

 Development Plan: Appendix 3 
 Development Plans for MAO B Antagonists **** and **** 
 **** Core Programme in Alzheimer’s disease 
 Regulatory 
 Transfer ownership of CTAs and update as necessary (Q12006)

 Compound Supply 
 Prepare Clinical Trial Material from
existing drug product where available, or existing drug substance to support Phase I programme (Q1 2006) 
 Prepare Clinical Trial supplies from existing
drug substance to support Phase II programme (Q1 and Q2 2006) 
 Phase I 
 One month safety and tolerability with pharmacokinetics in young healthy subjects and healthy elderly volunteers 
 Study conduct during H1 2006

 Possible assessment of central MAO B Inhibition using PET imaging, following repeat dosing with **** of approx two weeks to one months duration in healthy
elderly subjects and in a small number of patients with Alzheimer’s disease at pharmacokinetic steady state (approx 2-3 patients) mid 2006 
 Possible
Phase I drug-drug pharmacokinetic interaction study between **** and **** used in Alzheimer’s disease **** if required, conducted during Q2 2006 
 Phase II 
 One year double blind dose ranging study in patients with mild to moderate Alzheimer’s disease 
 Study will be conducted in patients not receiving **** if feasible, but this may require review following assembly of expert panel and further detailed feasibility
assessment 
 Commence Q3/Q4 2006 with Headline Data Q3 2008 
 A
further one year extension study may be incorporated into this programme, for patients who have entered the initial randomised one year phase II study mid 2008-mid 2009 
 **** 
 Regulatory 
 If required
Prepare IMPD to support Phase I (Q3 2006) 
 Compound Supply 
  
  
 * Portions of this document marked with **** have been
omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 1 

 If required prepare Clinical Trials material from existing drug substance or drug product as available to support Phase I
study Q3 2006 
 Phase I 
 Multiple ascending-dose Phase I study
in young and elderly healthy volunteers with assessment of safety, tolerability and pharmacokinetics. 
 Possible assessment of central MAO B Inhibition in
healthy elderly volunteers using PET imaging after repeated dosing to steady state 
 This investigation will be initiated in the event of untoward events
with the lead compound **** following the planned Phase I studies for that compound, in order to develop **** as a back up molecule in Alzheimer’s disease Study Conduct, if required in H2 2006/H1 2007 
 Preclinical Animal Toxicology 
 If required conduct additional longer term
toxicology studies to support Phase II indications 
 Other indications 
 At present it is not intended to develop these compounds in Parkinson’s disease 
 Further consideration will be given to performing a proof of
concept study dependent on the results of the ongoing programme in Alzheimer’s disease. 
  
  
 * Portions of this document marked with **** have been
omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 2 

 Related Patent Rights: Appendix 4 (MAOB – ****) 
  

																			
	 Country
 Code
	  	 Country
	  	Filing Date	  	Application No.	  	Publication No.	  	Patent
No.	  	Grant
Date	  	Expiry
Date	  	 Status
	  	 Holder

	 ****
	  	 ****
	  	****	  	****	  	****	  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  	****	  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  	****	  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  	****	  		  		  		  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  		  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  	****	  	****	  	****	  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  	****	  	****	  	****	  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  	****	  		  		  		  	 ****
	  	Roche Basel

  
 * Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 1 

 Related Patent Rights: Appendix 4 (MAOB – ****) 
  

																			
	 Country
Code
	  	 Country
	  	Filing Date	  	Application No.	  	Publication No.	  	Patent
No.	  	Grant
Date	  	Expiry
Date	  	 Status
	  	 Holder

	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  		  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  	****	  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  	****	  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  		  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  		  		  		  		  		  		  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  		  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  	****	  	****	  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  		  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  		  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  	****	  	****	  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  		  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  	****	  		  		  		  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  		  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  	****	  	****	  	****	  	****	  	 ****
	  	Roche Basel

  
 * Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 2 

																			
		  		  		  		  	****	  		  		  		  		  	
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	****	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  		  	****	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  		  	****	  	Roche Basel

  
 * Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 3 

 Related Patent Rights: Appendix 4 (MAOB – ****) 
  

																			
	 Country
Code
	  	 Country
	  	Filing Date	  	Application No.	  	Publication No.	  	Patent
No.	  	Grant
Date	  	Expiry
Date	  	 Status
	  	 Holder

	 ****
	  	 ****
	  	****	  	****	  	****	  		  		  	****	  	****	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	****	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	****	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	****	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  		  	****	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  	****	  		  		  	****	  	****	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  		  	****	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	****	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	****	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	****	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  	****	  		  		  	****	  	****	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	****	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  		  	****	  	Roche Basel
	 ****
	  	 ****
	  		  		  		  		  		  		  	****	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  		  	****	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  	****	  		  		  	****	  	****	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	****	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  	****	  		  		  		  	****	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	****	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  	****	  	****	  	****	  	****	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  		  	****	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  		  	****	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	****	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  	****	  	****	  	****	  	****	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	****	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	****	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	****	  	Roche Basel

  
 * Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 4 

																			
	 ****
	  	 ****
	  	****	  	****	  		  		  		  		  	****	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  		  	****	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	****	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	****	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  		  	****	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  		  	****	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	****	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  	****	  		  		  		  	****	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  	****	  		  		  		  	****	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  	****	  	****	  	****	  	****	  	****	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	****	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  		  	****	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  	****	  		  		  		  	****	  	Roche Basel

  
 * Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 5 

 Related Patent Rights: Appendix 4 (MAOB – ****) 
  

																			
	 Country
Code
	  	 Country
	  	Filing Date	  	Application No.	  	Publication No.	  	Patent
No.	  	Grant
Date	  	Expiry
Date	  	 Status
	  	 Holder

	 ****
	  	 ****
	  	****	  	****	  	****	  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  		  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  	****	  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  		  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  		  		  		  		  		  		  		  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  		  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  	****	  	****	  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  		  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  		  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  	****	  	****	  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  		  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  		  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  	****	  		  		  		  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  	****	  		  		  		  	 ****
	  	Roche Basel

  
 * Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 6 

																			
	 ****
	  	 ****
	  	****	  	****	  	****	  		  		  		  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  		  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  	****	  		  		  		  	 ****
	  	Roche Basel

  
 * Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 7 

 Related Patent Rights: Appendix 4 (MAOB – ****) 
  

																			
	 Country
Code
	  	 Country
	  	Filing Date	  	Application No.	  	Publication No.	  	Patent
No.	  	Grant
Date	  	Expiry
Date	  	 Status
	  	 Holder

	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  		  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  	****	  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  	****	  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  		  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  		  		  		  		  		  		  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  	****	  		  		  		  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  	****	  	****	  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  		  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  		  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  	****	  	****	  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  		  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  	****	  		  		  		  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  		  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  	****	  	****	  	****	  	****	  	 ****
	  	Roche Basel

  
 * Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 8 

																			
		  		  		  		  	****	  		  		  		  		  	
	 ****
	  	 ****
	  	****	  	****	  		  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  		  		  		  		  	 ****
	  	Roche Basel
	 ****
	  	 ****
	  	****	  	****	  	****	  		  		  		  	 ****
	  	Roche Basel

  
 * Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 
  

 9 

 APPENDIX 4- MAOB – **** 
  

																			
	 Country Code
	  	Country	 	Filing Date	  	Application No.	  	Publication No.	  	Patent No.	  	Grant Date	  	Expiry Date	  	Status	  	 Holder

	****	  	****	 	****	  	****	  		  		  		  	****	  	****	  	Roche Basel
	****	  	****	 	****	  	****	  		  		  		  	****	  	****	  	Roche Basel
	****	  	****	 	****	  	****	  		  		  		  	****	  	****	  	Roche Basel
	****	  	****	 	****	  	****	  		  		  		  	****	  	****	  	Roche Basel
	****	  	****	 	****	  	****	  		  		  		  		  	****	  	Roche Basel
	****	  	****	 	****	  	****	  	****	  		  		  	****	  	****	  	Roche Basel
	****	  	****	 	****	  	****	  		  		  		  	****	  	****	  	Roche Basel
	****	  	****	 	****	  	****	  		  		  		  	****	  	****	  	Roche Basel
	****	  	****	 	****	  	****	  	****	  		  		  	****	  	****	  	Roche Basel
	****	  	****	 	****	  	****	  		  		  		  	****	  	****	  	Roche Basel
	****	  	****	 	****	  	****	  		  		  		  		  	****	  	Roche Basel
	****	  	****	 		  		  		  		  		  		  	****	  	Roche Basel
	****	  	****	 	****	  	****	  	****	  		  		  		  	****	  	Roche Basel
	****	  	****	 	****	  	****	  		  		  		  	****	  	****	  	Roche Basel
	****	  	****	 	****	  	****	  		  	****	  	****	  	****	  	****	  	Roche Basel
	****	  	****	 	****	  	****	  		  		  		  		  	****	  	Roche Basel
	****	  	****	 	****	  	****	  		  		  		  		  	****	  	Roche Basel
	****	  	****	 	****	  	****	  		  	****	  	****	  	****	  	****	  	Roche Basel
	****	  	****	 	****	  	****	  		  		  		  	****	  	****	  	Roche Basel
	****	  	****	 	****	  	****	  		  		  		  	****	  	****	  	Roche Basel
	****	  	****	 	****	  	****	  		  		  		  		  	****	  	Roche Basel
	****	  	****	 	****	  	****	  		  		  		  	****	  	****	  	Roche Basel
	****	  	****	 	****	  	****	  		  		  		  	****	  	****	  	Roche Basel
	****	  	****	 	****	  	****	  		  		  		  	****	  	****	  	Roche Basel
	****	  	****	 	****	  	****	  	****	  		  		  		  	****	  	Roche Basel
	****	  	****	 	****	  	****	  		  		  		  		  	****	  	Roche Basel
	****	  	****	 	****	  	****	  	****	  	****	  	****	  	****	  	****	  	Roche Basel
	****	  	****	 	****	  	****	  	****	  	****	  	****	  	****	  	****	  	Roche Basel

  
 * Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 

																			
	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 
	****	  	****	  	****	  	****	  		  		  		  		  	****	  	Roche Basel
	****	  	****	  	****	  	****	  	****	  		  		  		  	****	  	Roche Basel

  
 * Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 

 APPENDIX 4- MAOB – **** 
  

																			
	 Country Code
	  	Country	  	Filing Date	  	Application No.	  	Publication No.	  	Patent No.	  	Grant Date	  	Expiry Date	  	Status	  	 Holder

	****	  	****	  	****	  	****	  	****	  		  		  	****	  	****	  	Roche Basel
	****	  	****	  	****	  	****	  		  		  		  	****	  	****	  	Roche Basel
	****	  	****	  	****	  	****	  		  		  		  	****	  	****	  	Roche Basel
	****	  	****	  	****	  	****	  		  		  		  	****	  	****	  	Roche Basel
	****	  	****	  	****	  	****	  		  		  		  		  	****	  	Roche Basel
	****	  	****	  	****	  	****	  	****	  		  		  	****	  	****	  	Roche Basel
	****	  	****	  	****	  	****	  		  		  		  		  	****	  	Roche Basel
	****	  	****	  	****	  	****	  		  		  		  	****	  	****	  	Roche Basel
	****	  	****	  	****	  	****	  		  		  		  	****	  	****	  	Roche Basel
	****	  	****	  	****	  	****	  	****	  		  		  	****	  	****	  	Roche Basel
	****	  	****	  	****	  	****	  		  		  		  	****	  	****	  	Roche Basel
	****	  	****	  	****	  	****	  		  		  		  		  	****	  	Roche Basel
	****	  	****	  		  		  		  		  		  		  		  	Roche Basel
	****	  	****	  	****	  	****	  		  		  		  	****	  	****	  	Roche Basel
	****	  	****	  	****	  	****	  	****	  		  		  	****	  	****	  	Roche Basel
	****	  	****	  	****	  	****	  		  		  		  	****	  	****	  	Roche Basel
	****	  	****	  	****	  	****	  		  		  		  		  	****	  	Roche Basel
	****	  	****	  	****	  	****	  		  		  		  	****	  	****	  	Roche Basel
	****	  	****	  	****	  	****	  		  	****	  	****	  	****	  	****	  	Roche Basel
	****	  	****	  	****	  	****	  		  		  		  		  	****	  	Roche Basel
	****	  	****	  	****	  	****	  		  		  		  		  	****	  	Roche Basel
	****	  	****	  	****	  	****	  		  		  		  	****	  	****	  	Roche Basel
	****	  	****	  	****	  	****	  		  	****	  	****	  	****	  	****	  	Roche Basel
	****	  	****	  	****	  	****	  		  		  		  	****	  	****	  	Roche Basel
	****	  	****	  	****	  	****	  		  		  		  	****	  	****	  	Roche Basel
	****	  	****	  	****	  	****	  		  	****	  	****	  	****	  	****	  	Roche Basel
	****	  	****	  	****	  	****	  		  		  		  		  	****	  	Roche Basel
	****	  	****	  	****	  	****	  		  		  		  		  	****	  	Roche Basel

  
 * Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 

																			
	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 
	****	  	****	  	****	  	****	  		  		  		  	****	  	****	  	Roche Basel
	****	  	****	  	****	  	****	  		  		  		  	****	  	****	  	Roche Basel
	****	  	****	  	****	  	****	  		  		  		  		  	****	  	Roche Basel
	****	  	****	  	****	  	****	  		  		  		  		  	****	  	Roche Basel
	****	  	****	  	****	  	****	  		  		  		  	****	  	****	  	Roche Basel
	****	  	****	  	****	  	****	  	****	  		  		  		  	****	  	Roche Basel
	****	  	****	  	****	  	****	  		  		  		  		  	****	  	Roche Basel
	****	  	****	  	****	  	****	  	****	  		  		  		  	****	  	Roche Basel
	****	  	****	  	****	  	****	  		  		  		  	****	  	****	  	Roche Basel
	****	  	****	  	****	  	****	  		  		  		  		  	****	  	Roche Basel
	****	  	****	  	****	  	****	  	****	  		  		  		  	****	  	Roche Basel

  
 * Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 

 APPENDIX 4- MAOB – **** 
  

																			
	 Country Code
	  	Country	  	Filing Date	  	Application No.	  	Publication No.	  	Patent No.	  	Grant Date	  	Expiry Date	  	Status	  	 Holder

	****	  	****	  	****	  	****	  	****	  		  		  	****	  	****	  	Roche Basel
	****	  	****	  	****	  	****	  		  		  		  	****	  	****	  	Roche Basel
	****	  	****	  	****	  	****	  		  		  		  	****	  	****	  	Roche Basel
	****	  	****	  	****	  	****	  		  		  		  	****	  	****	  	Roche Basel
	****	  	****	  	****	  	****	  		  		  		  		  	****	  	Roche Basel
	****	  	****	  	****	  	****	  	****	  		  		  	****	  	****	  	Roche Basel
	****	  	****	  	****	  	****	  		  		  		  		  	****	  	Roche Basel
	****	  	****	  	****	  	****	  		  		  		  	****	  	****	  	Roche Basel
	****	  	****	  	****	  	****	  	****	  		  		  	****	  	****	  	Roche Basel
	****	  	****	  	****	  	****	  		  		  		  	****	  	****	  	Roche Basel
	****	  	****	  	****	  	****	  		  		  		  		  	****	  	Roche Basel
	****	  		  		  		  		  		  		  		  		  	Roche Basel
	****	  	****	  	****	  	****	  		  		  		  	****	  	****	  	Roche Basel
	****	  	****	  	****	  	****	  	****	  		  		  	****	  	****	  	Roche Basel
	****	  	****	  	****	  	****	  		  		  		  	****	  	****	  	Roche Basel
	****	  	****	  	****	  	****	  		  		  		  		  	****	  	Roche Basel
	****	  	****	  	****	  	****	  		  		  		  	****	  	****	  	Roche Basel
	****	  	****	  	****	  	****	  		  	****	  		  	****	  	****	  	Roche Basel
	****	  	****	  	****	  	****	  		  		  		  		  	****	  	Roche Basel
	****	  	****	  	****	  	****	  		  		  		  		  	****	  	Roche Basel
	****	  	****	  	****	  	****	  		  		  		  	****	  	****	  	Roche Basel
	****	  	****	  	****	  	****	  		  	****	  		  	****	  	****	  	Roche Basel
	****	  	****	  	****	  	****	  		  		  		  	****	  	****	  	Roche Basel
	****	  	****	  	****	  	****	  		  		  		  	****	  	****	  	Roche Basel
	****	  	****	  	****	  	****	  		  		  		  	****	  	****	  	Roche Basel
	****	  	****	  	****	  	****	  		  		  		  		  	****	  	Roche Basel
	****	  	****	  	****	  	****	  		  		  		  		  	****	  	Roche Basel
	****	  	****	  	****	  	****	  		  		  		  	****	  	****	  	Roche Basel

  
 * Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 

																			
	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 
	****	  	****	  	****	  	****	  		  		  		  	****	  	****	  	Roche Basel
	****	  	****	  	****	  	****	  		  		  		  		  	****	  	Roche Basel
	****	  	****	  	****	  	****	  		  		  		  		  	****	  	Roche Basel
	****	  	****	  	****	  	****	  		  		  		  	****	  	****	  	Roche Basel
	****	  	****	  	****	  	****	  	****	  		  		  		  	****	  	Roche Basel
	****	  	****	  	****	  	****	  		  		  		  		  	****	  	Roche Basel
	****	  	****	  	****	  	****	  	****	  		  		  		  	****	  	Roche Basel
	****	  	****	  	****	  	****	  		  		  		  	****	  	****	  	Roche Basel
	****	  	****	  	****	  	****	  		  		  		  		  	****	  	Roche Basel
	****	  	****	  	****	  	****	  	****	  		  		  		  	****	  	Roche Basel

  
 * Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC. 

 APPENDIX 4- MAOB – **** 
  

																			
	 Country Code
	  	 Country
	  	 Filing Date
	  	 Application No.
	  	 Publication No.
	  	 Patent No.
	  	 Grant Date
	  	 Expiry Date
	  	 Status
	  	 Holder

	 ****
	  	****	  	****	  	****	  	****	  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	****	  	****	  	****	  		  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	****	  	****	  	****	  		  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	****	  	****	  	****	  		  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	****	  	****	  	****	  	****	  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	****	  	****	  	****	  		  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	****	  	****	  	****	  	****	  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	****	  	****	  	****	  	****	  		  		  		  	 ****
	  	Roche Basel
	 ****
	  	****	  	****	  	****	  		  		  		  		  	 ****
	  	Roche Basel
	 ****
	  	****	  	****	  	****	  		  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	****	  	****	  	****	  		  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	****	  	****	  	****	  		  		  		  	****	  	 ****
	  	Roche Basel
	 ****
	  	****	  	****	  	****	  	****	  	****	  	****	  	****	  	 ****
	  	Roche Basel
	 ****
	  	****	  	****	  	****	  	****	  		  		  		  	 ****
	  	Roche Basel

  
 * Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00136-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00136-of-00352.parquet"}]]